Annual Reports

 
Quarterly Reports

 
8-K

 
Other

  • 424B4 (Apr 16, 2014)
  • EFFECT (Apr 15, 2014)
  • S-1 (Apr 14, 2014)
  • S-1 (Apr 11, 2014)
  • S-1 (Mar 24, 2014)
  • S-1 (Mar 7, 2014)
Cardica DEF 14A 2008

Documents found in this filing:

  1. Def 14A
  2. Graphic
  3. Graphic
def14a
Table of Contents

SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No.__)
     
Filed by the Registrant
  þ
Filed by a Party other than the Registrant
  o
Check the appropriate box:
     
o
  Preliminary Proxy Statement
o
  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
þ
  Definitive Proxy Statement
o
  Definitive Additional Materials
o
  Soliciting Material Pursuant to § 240.14a-12
CARDICA, INC.
 
(Name of Registrant as Specified In Its Charter)
 
(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box)
     
þ
  No fee required.
o
  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 
   
1.
  Title of each class of securities to which transaction applies:
 
   
 
 
   
2.
  Aggregate number of securities to which transaction applies:
 
   
 
 
   
3.
  Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
 
   
 
 
   
4.
  Proposed maximum aggregate value of transaction:
 
   
 
 
   
5.
  Total fee paid:
 
   
 
 
   
o
  Fee paid previously with preliminary materials.
 
   
o
  Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 
   
6.
  Amount Previously Paid:
 
   
 
 
   
7.
  Form, Schedule or Registration Statement No.:
 
   
 
 
   
8.
  Filing Party:
 
   
 
 
   
9.
  Date Filed:
 
   
 


TABLE OF CONTENTS

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
PROXY STATEMENT FOR THE 2008 ANNUAL MEETING OF STOCKHOLDERS
QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING
Proposal 1
The Board Of Directors Recommends A Vote In Favor Of Each Named Nominee.
INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE
Approval of an Amendment to the 2005 Equity Incentive Plan
Securities Authorized For Issuance Under Equity Compensation Plans
Security Ownership Of Certain Beneficial Owners And Management
AUDIT COMMITTEE AND INDEPENDENT AUDITOR INFORMATION
Principal Accountant Fees and Services
Proposal 3 RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL 2009
Executive Compensation
Transactions With Related Persons
Householding of Proxy Materials
Other Matters


Table of Contents

 
CARDICA, INC.
900 Saginaw Drive
Redwood City, California 94063
 
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
 
 
Dear Stockholder:
 
You are cordially invited to attend the Annual Meeting of Stockholders of Cardica, Inc., a Delaware corporation (the “Company”). The meeting will be held on November 19, 2008 at 11:30 a.m. local time at 900 Saginaw Drive, Redwood City, California 94063 for the following purposes:
 
1. To elect directors to hold office until the 2009 Annual Meeting and until their successors are elected and have qualified, or until such director’s death, resignation or removal.
 
2. To approve an amendment to our 2005 Equity Incentive Plan (the “2005 Plan”) to increase the aggregate number of shares of common stock authorized for issuance under the 2005 Plan by 500,000 shares.
 
3. To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending June 30, 2009.
 
4. To conduct any other business properly brought before the meeting.
 
These items of business are more fully described in the Proxy Statement accompanying this Notice.
 
The record date for the annual meeting is September 26, 2008. Only stockholders of record at the close of business on that date may vote at the meeting or any adjournment thereof.
 
By Order of the Board of Directors
 
-s- Robert Y. Newell
Robert Y. Newell
Secretary
 
Redwood City, California
October 9, 2008
 
 
You are cordially invited to attend the annual meeting in person. Whether or not you expect to attend the annual meeting, please complete, date, sign and return the enclosed proxy or vote over the telephone or the Internet as instructed in these materials, as promptly as possible in order to ensure your representation at the annual meeting. A return envelope (which is postage prepaid if mailed in the United States) is enclosed for your convenience. Even if you have voted by proxy, you may still vote in person if you attend the annual meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the annual meeting, you must obtain a proxy issued in your name from that broker, bank or other nominee.
 
 


Table of Contents

CARDICA, INC.
900 Saginaw Drive
Redwood City, California 94063

PROXY STATEMENT
FOR THE 2008 ANNUAL MEETING OF STOCKHOLDERS
November 19, 2008

QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING
 
 
We have sent you this proxy statement and the enclosed proxy card because the Board of Directors (the “Board”) of Cardica, Inc. (sometimes referred to as the “Company” or “Cardica”) is soliciting your proxy to vote at our 2008 annual meeting of stockholders, including at any adjournments or postponements of the meeting. You are invited to attend the annual meeting to vote on the proposals described in this proxy statement. However, you do not need to attend the meeting to vote your shares. Instead, you may simply complete, sign and return the enclosed proxy card, or follow the instructions below to submit your proxy over the telephone or on the Internet.
 
We intend to mail this proxy statement and accompanying proxy card on or about October 9, 2008 to all stockholders of record entitled to vote at the annual meeting.
 
 
Only stockholders of record at the close of business on September 26, 2008 will be entitled to vote at the annual meeting. On the record date, there were 15,804,925 shares of common stock outstanding and entitled to vote.
 
 
If on September 26, 2008 your shares were registered directly in your name with our transfer agent, Computershare, Inc., then you are a stockholder of record. As a stockholder of record, you may vote in person at the meeting or vote by proxy. Whether or not you plan to attend the annual meeting, we urge you to fill out and return the enclosed proxy card or vote by proxy over the telephone or on the Internet as instructed below to ensure your vote is counted.
 
 
If on September 26, 2008 your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of shares held in “street name” and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the annual meeting. As a beneficial owner, you have the right to direct your broker or other agent regarding how to vote the shares in your account. You are also invited to attend the annual meeting. However, since you are not the stockholder of record, you may not vote your shares in person at the annual meeting unless you request and obtain a valid proxy from your broker or other agent.
 
 
There are three matters scheduled for a vote at the annual meeting:
 
  •  Election of directors to hold office until the 2009 Annual Meeting and until their successors are elected and have qualified, or until such director’s death, resignation or removal;
 
  •  Approval of an amendment to our 2005 Equity Incentive Plan (the “2005 Plan”) to increase the aggregate number of shares of common stock authorized for issuance under the 2005 Plan by 500,000 shares;
 
  •  Ratification of the selection by the Audit Committee of the Board of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending June 30, 2009.


Table of Contents

 
 
You may either vote “For” all the nominees to our Board or you may “Withhold” your vote for any nominee you specify. For each of the other matters to be voted on, you may vote “For” or “Against” or abstain from voting. The procedures for voting are fairly simple:
 
 
If you are a stockholder of record, you may vote in person at the annual meeting, vote by proxy using the enclosed proxy card, vote by proxy over the telephone, or vote by proxy on the Internet. Whether or not you plan to attend the meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the meeting and vote in person even if you have already voted by proxy.
 
  •  To vote in person, come to the annual meeting and we will give you a ballot when you arrive.
 
  •  To vote using the proxy card, simply complete, sign and date the enclosed proxy card and return it promptly in the envelope provided. If you return your signed proxy card to us before the annual meeting, we will vote your shares as you direct.
 
  •  To vote over the telephone, dial the number provided on the enclosed proxy card using a touch-tone phone and follow the recorded instructions. You will be asked to provide the company number and control number from the enclosed proxy card. Your vote must be received by 1:00 a.m., Pacific Time on November 19, 2008 to be counted.
 
  •  To vote on the Internet, go to www.investorvote.com to complete an electronic proxy card. You will be asked to provide the company number and control number from the enclosed proxy card. Your vote must be received by 1:00 a.m., Pacific Time on November 19, 2008 to be counted.
 
 
If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a proxy card and voting instructions with these proxy materials from that organization rather than from us. Simply complete and mail the proxy card to ensure that your vote is counted. Alternatively, you may vote by telephone or over the Internet as instructed by your broker or bank. To vote in person at the annual meeting, you must obtain a valid proxy from your broker, bank, or other agent. Follow the instructions from your broker or bank included with these proxy materials, or contact your broker or bank to request a proxy form.
 
We provide Internet proxy voting to allow you to vote your shares on-line, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your Internet access, such as usage charges from Internet access providers and telephone companies.
 
 
On each matter to be voted upon, you have one vote for each share of common stock you owned as of September 26, 2008.
 
 
If you return a signed and dated proxy card without marking any voting selections, your shares will be voted “For” the election of all nine nominees for director, “For” the approval of the amendment to our 2005 Plan and “For” the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending June 30, 2009. If any other matter is properly presented at the annual meeting, your proxy (one of the individuals named on your proxy card) will vote your shares using his best judgment.


2


Table of Contents

 
We will pay for the entire cost of soliciting proxies. In addition to these mailed proxy materials, our directors and employees may also solicit proxies in person, by telephone or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners.
 
 
If you receive more than one proxy card, your shares are registered in more than one name or are registered in different accounts. Please complete, sign and return each proxy card to ensure that all of your shares are voted.
 
 
Yes. You can revoke your proxy at any time before the final vote at the annual meeting. If you are the record holder of your shares, you may revoke your proxy in any one of three ways:
 
  •  You may submit another properly completed proxy card with a later date.
 
  •  You may send a written notice that you are revoking your proxy to our Secretary, Robert Y. Newell, at 900 Saginaw Drive, Redwood City, California 94063.
 
  •  You may attend the annual meeting and vote in person. Simply attending the annual meeting will not, by itself, revoke your proxy.
 
If your shares are held by your broker or bank as a nominee or agent, you should follow the instructions provided by your broker or bank.
 
 
To be considered for inclusion in next year’s proxy materials, your proposal must be submitted in writing by June 11, 2009. If you wish to submit a proposal that is not to be included in next year’s proxy materials or nominate a director, you must do so by no later than the close of business on September 15, 2009 nor earlier than the close of business on August 15, 2009. Please review our Bylaws, which contain a description of the information required to be submitted as well as additional requirements about advance notice of stockholder proposals and director nominations.
 
If you wish to bring a proposal before the stockholders or nominate a director at the 2009 Annual Meeting of Stockholders, but you are not requesting that your proposal or nomination be included in next year’s proxy materials, you must notify our Corporate Secretary, in writing, not later than the close of business on September 20, 2009, and not earlier than the close of business on August 21, 2009. However, if our 2009 Annual Meeting of Stockholders is not held between October 20, 2009 and December 19, 2009, then the deadline for notifying our Corporate Secretary, in writing, will be not earlier than the close of business on the ninetieth (90th) day prior to the date of the 2009 Annual Meeting of Stockholders and not later than the close of business on the later of the sixtieth (60th) day prior the date of the 2009 Annual Meeting of Stockholders or, in the event public announcement of the date of the 2009 Annual Meeting of the Stockholders was first made by us fewer than seventy (70) days prior to the date of the 2009 Annual Meeting of Stockholders, the close of business on the tenth (10th) day following the date on which we first made a public announcement of the date of the 2009 Annual Meeting of Stockholders. The chairman of the 2009 Annual Meeting of Stockholders may determine, if the facts warrant, that a matter has not been properly brought before the meeting and, therefore, may not be considered at the meeting.
 
 
Votes will be counted by the inspector of election appointed for the annual meeting, who will separately count “For” and “Withhold” and, with respect to proposals other than the election of directors, “Against” votes, abstentions and broker non-votes. Abstentions will be counted towards the vote total for each proposal and will have the same effect as “Against” votes. Broker non-votes have no effect and will not be counted towards the vote total for any proposal.


3


Table of Contents

If your shares are held by your broker as your nominee (that is, in “street name”), you will need to obtain a proxy form from the institution that holds your shares and follow the instructions included on that form regarding how to instruct your broker to vote your shares. If you do not give instructions to your broker, your broker can vote your shares with respect to “discretionary” items such as electing directors and ratifying an independent registered public accounting firm, but not with respect to “non-discretionary” items. The shares that are not voted on non-discretionary matters are called broker non-votes. If you do not provide your broker with voting instructions on non-discretionary items, your shares will be treated as broker non-votes.
 
 
  •  For the election of directors, the nine nominees receiving the most “For” votes (among votes properly cast in person or by proxy) will be elected. Only votes “For” or “Withheld” will affect the outcome.
 
  •  To be approved, Proposal No. 2, to approve an amendment to the 2005 Plan to increase the aggregate number of shares of common stock authorized for issuance by 500,000 shares, must receive a “For” vote from the majority of shares present in person or represented by proxy at the annual meeting regarding Proposal No. 2. If you “Abstain” from voting, it will have the same effect as an “Against” vote. Broker non-votes will have no effect on this proposal.
 
  •  To be approved, Proposal No. 3, the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending June 30, 2009, must receive a “For” vote from the majority of shares present in person or represented by proxy at the annual meeting regarding Proposal No. 3. If you “Abstain” from voting, it will have the same effect as an “Against” vote. If you do not vote, it will have no effect. Broker non-votes will also have no effect on this proposal.
 
 
A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if at least a majority of the outstanding shares of stock entitled to vote are represented by stockholders present at the annual meeting in person or by proxy. On the record date, there were 15,804,925 shares outstanding and entitled to vote. Thus, 7,902,463 shares must be represented by stockholders present at the annual meeting in person or by proxy to have a quorum.
 
Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote in person at the annual meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If there is not a quorum, a majority of the votes present at the annual meeting may adjourn the annual meeting to another date.
 
 
Preliminary voting results will be announced at the annual meeting. Final voting results will be published in our quarterly report on Form 10-Q for the fiscal quarter ending December 31, 2008.


4


Table of Contents

Proposal 1
 
 
Our Board consists of nine directors. There are nine nominees for director this year. Each director to be elected will hold office until the next annual meeting of stockholders and until his successor is elected and qualified or until the director’s death, resignation or removal. Each of the nominees listed below is currently a director who was previously elected by our stockholders. It is our policy to encourage nominees for director to attend the annual meeting. Nine directors attended our 2007 annual meeting.
 
Directors are elected by a plurality of the votes properly cast in person or by proxy. The nine nominees receiving the highest number of affirmative votes will be elected. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the nine nominees named below. If any nominee becomes unavailable for election as a result of an unexpected occurrence, your shares will be voted for the election of a substitute nominee proposed by or Nominating and Corporate Governance Committee. Each person nominated for election has agreed to serve if elected. Our management has no reason to believe that any nominee will be unable to serve.
 
 
The following is a brief biography of each nominee for director and their ages as of September 30, 2008.
 
             
Name
 
Age
 
Principal Position With the Company
 
Bernard A. Hausen, M.D., Ph.D. 
    48     President, Chief Executive Officer, Chief Medical Officer and Director
J. Michael Egan
    58     Director
Kevin T. Larkin
    59     Chairman of the Board
Richard P. Powers
    64     Director
Jeffrey L. Purvin
    56     Director
Robert C. Robbins, M.D. 
    50     Director
John Simon, Ph.D. 
    65     Director
Stephen A. Yencho, Ph.D. 
    47     Director
William H. Younger, Jr. 
    58     Director
 
Bernard A. Hausen, M.D., Ph.D. has been our President and Chief Executive Officer since December 2000. Dr. Hausen co-founded the Company in October 1997 and has served as a director and our Chief Medical Officer since inception. Dr. Hausen received a medical degree from Hannover Medical School in Germany in 1988 and was trained there as a general and cardiothoracic surgeon. Upon completion of his training, he received a Ph.D. degree in Medical Physiology in 1999. From 1996 to 2000, he was employed as a Senior Research Scientist in the Laboratory for Transplantation Immunology of the Department of Cardiothoracic Surgery at Stanford University. Until Dr. Hausen became our full-time employee in October of 2000, he remained responsible for all surgery-related research in that laboratory.
 
J. Michael Egan has been a director since August 2000 and served as the Chairman of the Board from August 2000 until January 2007. Since November 2006, Mr. Egan has been the Chief Executive Officer of Steadman Hawkins Research Foundation, an orthopedic research organization. From April 1996 through May 2004, Mr. Egan was President and CEO of Bluebird Development, LLC, a financial partnership with Kobayashi Pharmaceutical Company, an Osaka, Japan-based major distributor of medical devices in Asia. Mr. Egan is the Chairman of the Board of Directors at iBalance Medical, a privately held medical device company, and is a director of several privately held companies and of Western Technology Investment, a registered investment company. Mr. Egan holds a B.A. degree in Business Administration from Colorado College.
 
Kevin T. Larkin has been a director since December 2005 and was elected Chairman of the Board in January 2007. Mr. Larkin has been President, Chief Executive Officer and a director of TherOx, a medical device company, since May 2001. From July 1998 until April 2001, Mr. Larkin was President and Chief Executive Officer of CardioVasc, a medical device company. Mr. Larkin also has held senior sales and marketing management positions with Ventritex, Medtronic and Cordis.


5


Table of Contents

Richard P. Powers has been a director and chairman of our Audit Committee since October 2005. Since June 2008, Mr. Powers has been President and CEO of Aspire Medical Inc., a privately held medical device company developing products for the treatment of obstructive sleep apnea. From October 2001 to March 2008, Mr. Powers was Vice President and Chief Financial Officer of Anesiva, Inc. (formerly Corgentech Inc.), a biotechnology company. From March 1999 to August 2000, Mr. Powers served as Executive Vice President and Chief Financial Officer of Eclipse Surgical Technologies, Inc., a medical device company. From February 1996 to March 1999, Mr. Powers served as Executive Vice President and Chief Financial Officer of CardioGenesis Corporation, a medical device company. From January 1981 to August 1995, Mr. Powers held a number of senior management positions at Syntex Corporation, a biopharmaceutical company, including Senior Vice President and Chief Financial Officer. Mr. Powers holds a B.S. degree in Accounting from Canisius College and an M.B.A. degree from the University of Rochester, New York.
 
Jeffrey L. Purvin has been a director since August 2006. Since November 2006, Mr. Purvin has been chairman, president and chief executive officer of Calibra Medical, Inc. (formerly Seattle Medical Technologies, Inc.), a privately held medical company developing therapies for the treatment of diabetes. Mr. Purvin was the chairman and chief executive officer of Metrika, Inc., a privately held manufacturer and marketer of multi-use disposable diabetes monitoring products, from November 2004 until July 2006, when the company was sold to the Bayer Group. Prior to Metrika, Mr. Purvin was president of the Interventional Products Division of Datascope Corporation, a diversified medical device company, from April 2001 until October 2004. Before Datascope, Mr. Purvin spent more than 20 years at GlaxoSmithKline, where he concluded his service as vice president, general manager. Mr. Purvin earned his M.B.A. in marketing at The Wharton School, University of Pennsylvania and his BA in psychology from Brown University.
 
Robert C. Robbins, M.D. has been a director since January 2001 and has been one of our scientific advisors since October 1997. Dr. Robbins is the Chairman of the Department of Cardiothoracic Surgery at the Stanford University School of Medicine, where he has been a member of the faculty since 1993. Dr. Robbins is also the director of the Stanford Cardiovascular Institute. Previously, Dr. Robbins was a Pediatric Fellow of Cardiothoracic Surgery at Emory University, and Royal Children’s Hospital in Melbourne, Australia. Dr. Robbins is a former guest editor for the Surgical Supplement of Circulation and is a manuscript reviewer for a number of periodicals, including the New England Journal of Medicine and the Annals of Thoracic Surgery. He is also on the editorial board for the Journal of Thoracic and Cardiovascular Surgery. Dr. Robbins is certified by the American Board of Surgery and American Board of Thoracic Surgery. Dr. Robbins holds a B.S. degree from Millsaps College and an M.D. degree from the University of Mississippi Medical Center. Dr. Robbins completed his residency in Cardiothoracic Surgery at Stanford.
 
John Simon, Ph.D. has been a director since June 2001. Mr. Simon is a Managing Director of the investment banking firm, Allen & Company LLC, where he has been employed for over 25 years. He currently serves on the board of directors for Neurogen Corporation, as well as on the boards of several privately held companies. Mr. Simon holds a B.S. degree in Chemistry from The College of William & Mary, a Ph.D. degree in Chemical Engineering from Rice University, and both an M.B.A. degree in finance and a J.D. degree from Columbia University.
 
Stephen A. Yencho, Ph.D. has been a director since inception. Dr. Yencho co-founded Cardica in October 1997 with Dr. Hausen. From October 1997 through December 2000, Dr. Yencho was our chief executive officer. From December 2000 through July 2003, Dr. Yencho was our Chief Technology Officer, and Dr. Yencho provided consulting services to us until February 2004. Since February 2004, Dr. Yencho has been engaged in the development of early stage ventures separate from us. Dr. Yencho holds a B.S. degree in Mechanical Engineering from the University of Illinois and an M.S. degree in Manufacturing Systems Engineering from Stanford University. In addition, Dr. Yencho was sponsored by a Hewlett Packard Fellowship in the Ph.D. program in Precision Machinery Engineering at the University of Tokyo. He holds a Ph.D. degree in Materials Science and Engineering from Stanford University.
 
William H. Younger, Jr. has been a director since August 2000. Mr. Younger is a managing director of the general partner of Sutter Hill Ventures, a venture capital firm, where he has been employed since 1981. Mr. Younger holds a B.S. degree in Electrical Engineering from the University of Michigan and an M.B.A. degree from Stanford University. Mr. Younger is also a director of Omnicell, Inc., as well as of several privately held companies.
 
The Board Of Directors Recommends
A Vote In Favor Of Each Named Nominee.


6


Table of Contents

 
INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE
 
 
As required under the NASDAQ Global Market (“NASDAQ”) listing standards, a majority of the members of a listed company’s board of directors must qualify as “independent,” as affirmatively determined by the board of directors. Our Board consults with our counsel to ensure that the Board’s determinations are consistent with all relevant securities and other laws and regulations regarding the definition of “independent,” including those set forth in pertinent listing standards of the NASDAQ, as in effect from time to time.
 
Consistent with these considerations, after review of all relevant transactions or relationships between each director, or any of his family members, and us, our senior management and our independent registered public accounting firm, the Board has affirmatively determined the following directors are independent directors within the meaning of the applicable NASDAQ listing standards: J. Michael Egan, Kevin T. Larkin, Richard P. Powers, Jeffrey L. Purvin, Robert C. Robbins, Stephen A. Yencho and William H. Younger, Jr. In making this determination, the Board found that none of these directors have a material or other disqualifying relationship with us. Dr. Hausen and Mr. Simon do not qualify as independent directors because Dr. Hausen is one of our executive officers and Mr. Simon is affiliated with an entity that both owns a substantial percentage of our common stock and has received fees for services as an underwriter of our common stock.
 
Persons interested in communicating with the independent directors with their concerns or issues may address correspondence to a particular director, or to the independent directors generally, in care of Cardica, Inc. at 900 Saginaw Drive, Redwood City, California 94063. If no particular director is named, letters will be forwarded, depending on the subject matter, to the Chair of the Audit, Compensation or Nominating Committee of the Board.
 
 
The Board has three committees: an Audit Committee, a Compensation Committee and a Nominating Committee. The following table provides membership and meeting information for fiscal 2008 for each of the Board committees:
 
                         
Name
  Audit     Compensation     Nominating  
 
Bernard A. Hausen, M.D., Ph.D.
                       
J. Michael Egan
    X                  
Kevin T. Larkin
            X       X  
Richard P. Powers
    X *                
Jeffrey L. Purvin
            X *     X  
Robert C. Robbins, M.D. 
            X          
John Simon, Ph.D.
                       
Stephen A. Yencho, Ph.D.
                       
William H. Younger, Jr. 
    X               X *
Total meetings in fiscal 2008
    10       2       1  
 
 
* Committee Chairperson
 
Below is a description of each committee of the Board. Each of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities. The Board has determined that except as specifically described below, each member of each committee meets the applicable rules and regulations regarding “independence” and that each member is free of any relationship that would interfere with his individual exercise of independent judgment with regard to us.
 
 
The Audit Committee of the Board oversees our corporate accounting and financial reporting process. For this purpose, the Audit Committee performs several functions. The Audit Committee evaluates the performance of and


7


Table of Contents

assesses the qualifications of the independent registered public accounting firm; determines and approves the engagement of the independent registered public accounting firm; determines whether to retain or terminate the existing independent registered public accounting firm or to appoint and engage a new independent registered public accounting firm; reviews and approves the retention of the independent registered public accounting firm to perform any proposed permissible non-audit services; monitors the rotation of partners of the independent registered public accounting firm on our audit engagement team as required by law; oversees and assesses the independence of the auditors; reviews with management financial information and earnings guidance provided to analysts and issued in press releases; confers with management and the independent registered public accounting firm regarding the effectiveness of internal controls over financial reporting; establishes procedures, as required under applicable law, for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; reviews with management and the independent registered public accounting firm our major financial risk exposures; reviews with the independent registered public accounting firm, and management if appropriate, any management or internal control letter issued by the independent registered public accounting firm, including any response thereto by management; periodically meets in separate sessions with the independent registered public accounting firm and management to discuss matters that any such party believes should be discussed privately with the Audit Committee; reviews with counsel, the independent registered public accounting firm and management any significant regulatory, other legal or any accounting initiatives or matters that may have a material impact on our financial statements, compliance programs or policies; reviews the results of management’s efforts to monitor compliance with the law and our Code of Business Conduct and Ethics; investigates any matter brought to the attention of the Audit Committee; prepares the report to be included in our annual proxy statement; reviews and assesses the adequacy of the Audit Committee’s Charter each year; and meets to review our annual audited financial statements and quarterly financial statements with management and the independent registered public accounting firm, including reviewing our disclosures under “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Our Audit Committee charter can be found on our corporate website at www.cardica.com. The Audit Committee of the Board met ten times during fiscal 2008.
 
Our Board annually reviews the NASDAQ listing standards definition of independence for Audit Committee members and has determined that all of the members of our Audit Committee are independent (as independence is currently defined in Rule 4200(a)(15) and Rule 4350(d)(2)(A)(i) and (ii) of the NASDAQ listing standards and Rule 10A-3(b) of the Securities Exchange Act of 1934, as amended). The Board has determined that Richard P. Powers qualifies as an “audit committee financial expert,” as defined in the applicable U.S. Securities and Exchange Commission (the “SEC”) rules. The Board made a qualitative assessment of Mr. Powers’ level of knowledge and experience based on a number of factors, including his formal education and experience as a chief financial officer for public reporting companies.
 
 
The Compensation Committee of the Board reviews, modifies (as needed) and approves our overall compensation strategy and policies. In fulfilling these duties, the Compensation Committee is responsible for: reviewing and approving corporate performance goals and objectives relevant to the compensation of our executive officers and other senior management, as appropriate; evaluating and recommending to the Board for approval the compensation plans and programs advisable for us, as well as evaluating and recommending to the Board for approval the modification or termination of existing plans and programs; establishing policies with respect to equity compensation arrangements; and reviewing and approving the terms of any employment agreements, severance arrangements for our executive officers. The Compensation Committee also is responsible for recommending to the Board for determination and approval the compensation and other employment terms of our Chief Executive Officer, and is charged with evaluating the Chief Executive Officer’s performance in light of relevant corporate performance goals. The Committee recommends to the Board for determination and approval the compensation and other terms of employment of the other executive officers; reviews and recommends to the Board the type and amount of compensation to be paid or awarded to Board members; reviews and establishes appropriate insurance coverage for our directors and executive officers; reviews and assesses its own performance at least annually; and reviews and assesses the adequacy of Compensation Committee’s charter, and recommends any proposed changes to the Board for its consideration.


8


Table of Contents

The Compensation Committee also reviews with management our Compensation Discussion and Analysis and considers whether to recommend that it be included in proxy statements and other filings.
 
Our Compensation Committee charter can be found on our corporate website at www.cardica.com. All of the members of the Compensation Committee are independent (as independence is currently defined in Rule 4200(a)(15) of the NASDAQ listing standards). The Compensation Committee met two times during fiscal 2008.
 
 
The Nominating Committee of the Board is responsible for identifying, reviewing and evaluating candidates to serve as directors (consistent with criteria approved by the Board); reviewing and evaluating incumbent directors; serving as the focal point for communication between such candidates, non-committee directors and our management; recommending annually to the Board the chairmanship and membership of each Board committee; recommending to the Board for selection candidates for election to the Board; and reviewing and assessing the adequacy of the Nominating Committee’s charter. Our Nominating Committee charter can be found on our corporate website at www.cardica.com. All members of the Nominating Committee are independent (as independence is currently defined in Rule 4200(a)(15) of the NASDAQ listing standards). The Nominating Committee met once during fiscal 2008.
 
The Nominating Committee believes that candidates for director should have certain minimum qualifications, including being able to read and understand basic financial statements, being over 21 years of age and having the highest personal integrity and ethics. The Nominating Committee also intends to consider such factors as possessing relevant expertise upon which to be able to offer advice and guidance to management, having sufficient time to devote to our affairs, demonstrated excellence in his or her field, having the ability to exercise sound business judgment and having the commitment to rigorously represent the long-term interests of our stockholders. However, the Nominating Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the Board, our operating requirements and the long-term interests of stockholders. In conducting this assessment, the Nominating Committee considers diversity, experience, skills and such other factors as it deems appropriate given the Board’s and our current needs, to maintain a balance of knowledge, experience and capability. In the case of incumbent directors whose terms of office are set to expire, the Nominating Committee also reviews each of such director’s overall service to us during their term, including level of participation, quality of performance and any other relationships and transactions that might impair such director’s independence. In the case of new director candidates, the Nominating Committee also determines whether the nominee must be, and whether the nominee is, independent under applicable NASDAQ and SEC requirements, which determination is based upon applicable NASDAQ listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. The Nominating Committee then uses its network of contacts to compile a list of potential candidates, but may also engage, if it deems appropriate, a professional search firm. The Nominating Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board. The Nominating Committee meets to discuss and consider such candidates’ qualifications and then selects nominees for recommendation to the Board by majority vote. To date, the Nominating Committee has not paid a fee to any third party to assist in the process of identifying or evaluating director candidates. To date, the Nominating Committee has not received any director nominees from a stockholder or stockholders who are not members of our Board or management.
 
The Nominating Committee will consider director candidates recommended by stockholders. The Nominating Committee does not intend to alter the manner in which it evaluates candidates, including the minimum criteria set forth above, based on whether or not the candidate was recommended by a stockholder. Stockholders who wish to recommend individuals for consideration by the Nominating Committee to become nominees for election to the Board may do so by delivering a written recommendation to the Nominating Committee at the following address: 900 Saginaw Drive, Redwood City, California 94063 in accordance with Section 5(c) of our Bylaws. Submissions must include the full name of the proposed nominee, a description of the proposed nominee’s business experience for at least the previous five years, complete biographical information, a description of the proposed nominee’s qualifications as a director and a representation that the nominating stockholder is a beneficial or record owner of


9


Table of Contents

our stock. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected.
 
 
Our Board met eight times during fiscal 2008. All directors except Mr. Robbins attended at least 75% of the aggregate of the meetings of the Board and of the committees on which they served, held during the period for which they were directors or committee members, respectively. Mr. Robbins attended three of the eight meetings of the Board held during fiscal 2008, and all meetings of the Compensation Committee of the Board held during fiscal 2008.
 
 
Stockholders wishing to communicate with the Board or an individual director may send a written communication addressed as follows: Cardica Board Communication, 900 Saginaw Drive, Redwood City, CA 94063. Any communication sent must state the number of shares owned by the stockholder making the communication. The Chief Financial Officer will review each communication and will forward such communication to the Board or to any individual director to whom the communication is addressed.
 
 
The Board adopted the Cardica, Inc. Code of Business Conduct and Ethics that applies to all officers, directors and employees. The Code of Business Conduct and Ethics is available on our website at www.cardica.com. If we make any substantive amendments to the Code of Business Conduct and Ethics or grant any waiver from a provision of the Code to any executive officer or director, we will promptly disclose the nature of the amendment or waiver on our website. On May 7, 2008 the Board amended the Code of Business Conduct and Ethics to permit and provide the process for anonymous reporting of possible misconduct through a third party provider.
 
 
Typically, our Compensation Committee meets at least twice annually and with greater frequency if necessary. The agenda for each meeting is usually developed by the Chair of the Compensation Committee, in consultation with the CEO. The Compensation Committee meets regularly in executive session. However, from time to time, various members of management and other employees as well as outside advisors or consultants may be invited by the Compensation Committee to make presentations, provide financial or other background information or advice or otherwise participate in Compensation Committee meetings. The Chief Executive Officer may not participate in or be present during any deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives. The charter of the Compensation Committee grants the Compensation Committee full access to all our books, records, facilities and personnel, as well as authority to obtain, at our expense, advice and assistance from internal and external legal, accounting or other advisors and consultants and other external resources that the Compensation Committee considers necessary or appropriate in the performance of its duties. In particular, the Compensation Committee has the sole authority to retain compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve the consultant’s reasonable fees and other retention terms.
 
Historically, the Compensation Committee has made most significant adjustments to annual compensation, determined bonus and equity awards and established new performance objectives at one or more meetings held during the first quarter of the fiscal year. However, the Compensation Committee also considers matters related to individual compensation, such as compensation for new executive hires, as well as high-level strategic issues, such as the efficacy of our compensation strategy, potential modifications to that strategy and new trends, plans or approaches to compensation, at various meetings throughout the year. Generally, the Compensation Committee’s process comprises two related elements: the determination of compensation levels and the establishment of performance objectives for the current year. For executives other than the Chief Executive Officer, the Compensation Committee solicits and considers evaluations and recommendations submitted to the Committee by the Chief Executive Officer. In the case of the Chief Executive Officer, the performance evaluation is conducted by the


10


Table of Contents

Compensation Committee, which determines any adjustments to his compensation as well as awards to be granted. Generally, as part of the annual performance and compensation review of the Chief Executive Officer, the Compensation Committee formally requests and considers a fact-focused self assessment by the Chief Executive Officer. For all executives, as part of its deliberations, the Compensation Committee may review and consider, as appropriate, materials such as financial reports and projections, operational data, tax and accounting information, tally sheets that set forth the total compensation that may become payable to executives in various hypothetical scenarios, executive and director stock ownership information, company stock performance data, analyses of historical executive compensation levels and current company-wide compensation levels and recommendations of a compensation consultant including analyses of executive compensation paid at other companies identified by the consultant.
 
The specific determinations of the Compensation Committee with respect to executive compensation for fiscal 2008 are described in greater detail in the Compensation Discussion and Analysis section of this proxy statement.
 
 
None of the members of our Compensation Committee has at any time been one of our officers or employees. None of our executive officers currently serves, or in the past year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our Board or Compensation Committee. Information with respect to transactions between us and any member of the Compensation Committee are described under “Transactions With Related Persons.”
 
 
The Compensation Committee has reviewed and discussed with management the Compensation Discussion and Analysis (“CD&A”) contained in this proxy statement. Based on this review and discussion, the Compensation Committee has recommended to the Board that the CD&A be included in this proxy statement and incorporated into our Annual Report on Form 10-K for the fiscal year ended June 30, 2008.
 
Jeffrey L. Purvin, Chair
Kevin T. Larkin
Robert C. Robbins
 
 
   * The material in this report is not “soliciting material,” is furnished to, but not deemed “filed” with, the Commission and is not deemed to be incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, other than the Company’s Annual Report on Form 10-K, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.


11


Table of Contents

Proposal 2
 
 
In October 2005, our Board adopted, and in December 2005 our stockholders approved, our 2005 Equity Incentive Plan (as amended, the “2005 Plan”). The 2005 Plan became effective on February 2, 2006, and was amended by the Board on September 29, 2006 and October 10, 2007, with the amendments approved by our stockholders on November 8, 2006 and November 14, 2007, respectively. The 2005 Plan will terminate on October 12, 2015, unless terminated earlier by our Board.
 
As of September 1, 2008, awards covering an aggregate of 1,146,208 shares of common stock were outstanding under the 2005 Plan, and awards covering an aggregate of 582,596 shares of common stock were outstanding under the 1997 Equity Incentive Plan (the “1997 Plan”). The 1997 Plan has terminated, but there were options outstanding under the 1997 Plan prior to its termination that continue to be governed by the terms of the 1997 Plan. An aggregate of 19,098 shares of common stock have been issued pursuant to the exercise of awards issued under the 2005 Plan.
 
As of September 1, 2008, a total of 801,991 shares of common stock were included in the share reserve under the 2005 Plan, and 64,208 shares of common stock remained available for future grant under the 2005 Plan. In addition, if any stock award under the 1997 Plan expires or otherwise terminates, in whole or in part, without having been exercised in full, or if any shares of common stock issued pursuant to a stock award under the 1997 Plan are forfeited back to us because of the failure to meet a contingency or condition required to vest such shares in the holder of the stock award, the share reserve of the 2005 Plan automatically increases by the number of shares of common stock not acquired or forfeited. The number of shares available for future grant under the 2005 Plan will also increase if shares covered by outstanding awards revert to the 2005 Plan as discussed more fully below under the heading “General.”
 
Stockholders are requested in this Proposal No. 2 to approve the amendment to the 2005 Plan to increase the number of shares of common stock authorized for issuance thereunder by 500,000. The affirmative vote of the holders of a majority of the shares present in person or represented by proxy at the annual meeting regarding Proposal No. 2 will be required to approve the amendment to the 2005 Plan. Abstentions will be counted toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as negative votes. Broker non-votes are counted towards a quorum, but are not counted for any purpose in determining whether this matter has been approved.
 
The terms and provisions of the 2005 Plan, as amended, are summarized below. This summary, however, does not purport to be a complete description of the 2005 Plan. The 2005 Plan has been filed with the SEC as an attachment to this Proxy Statement and may be accessed from the SEC’s website at www.sec.gov. The following summary is qualified in its entirety by reference to the complete text of the 2005 Plan, as amended. Any stockholder that wishes to obtain a copy of the actual plan document may do so by written request to our Secretary at Cardica, Inc., 900 Saginaw Drive, Redwood City, California 94063.
 
 
The 2005 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock purchase awards, stock bonus awards, stock appreciation rights, stock unit awards and other forms of equity compensation, referred to collectively as stock awards, which may be granted to employees, including officers, non-employee directors and consultants. The Board or an authorized committee will, in its sole discretion, determine the criteria that will be used in selecting recipients of stock awards under the 2005 Plan.
 
The aggregate number of shares of common stock reserved for issuance under the 2005 Plan pursuant to stock awards will be 1,658,377 shares, if the amendment to the 2005 Plan is approved. In addition, if any stock award under the 1997 Plan expires or otherwise terminates, in whole or in part, without having been exercised in full, or if any shares of common stock issued pursuant to a stock award under the 1997 Plan are forfeited back to us because of the failure to meet a contingency or condition required to vest such shares in the holder of the stock award, the share reserve of the 2005 Plan automatically increases by the number of shares of common stock not acquired or forfeited.


12


Table of Contents

Shares issued under the 2005 Plan may again become available for the grant of new awards under the 2005 Plan if shares are:
 
  •  forfeited to or repurchased by us prior to becoming fully vested;
 
  •  withheld to satisfy income and employment withholding taxes;
 
  •  used to pay the exercise price of an option in a net exercise arrangement;
 
  •  tendered to us to pay the exercise price of an option; or
 
  •  cancelled pursuant to an exchange or repricing program approved by the stockholders
 
In addition, if a stock award granted under the 2005 Plan expires or otherwise terminates without being exercised in full, the shares of common stock not acquired pursuant to the award again become available for subsequent issuance under the 2005 Plan. Shares issued under the 2005 Plan may be previously unissued shares or reacquired shares we have bought on the market.
 
No person may be granted awards covering more than 200,000 shares of common stock under the 2005 Plan during any calendar year pursuant to an appreciation-only stock award. An appreciation-only stock award is a stock award whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the fair market value of our common stock on the date of grant. A stock option or stock appreciation right with an exercise or strike price equal to the value of the stock on the date of grant is an example of an appreciation-only award. This limitation is designed to help assure that any tax deductions to which we would otherwise be entitled upon the exercise of an appreciation-only stock award or upon the subsequent sale of shares purchased under such an award, will not be subject to the $1 million limitation on the income tax deductibility of compensation paid per covered executive officer imposed under Section 162(m) of the Internal Revenue Code (the “Code”). Stockholder approval of this Proposal 2 will also constitute a reapproval of the 200,000 share limitation on appreciation-only stock awards for purposes of Section 162(m) of the Code.
 
 
Our Board has delegated its authority to administer the 2005 Plan to our Compensation Committee. Subject to the terms of the 2005 Plan, our Board or an authorized committee, referred to as the plan administrator, determines recipients, dates of grant, the numbers and types of equity awards to be granted and the terms and conditions of the equity awards, including the period of their exercisability and vesting. Subject to the limitations set forth below, the plan administrator will also determine the exercise price of options granted, the purchase price of stock purchase awards and the strike price of stock appreciation rights.
 
The plan administrator does not have the authority to (a) reprice any outstanding stock award under the 2005 Plan after it has been granted, or (b) cancel and re-grant any outstanding stock award under the 2005 Plan, unless our stockholders have approved such an action within a 12 month period preceding or following such an event.
 
 
The plan administrator determines the exercise price for a stock option, within the terms and conditions of the 2005 Plan and applicable law, provided that the exercise price of an incentive or nonstatutory stock option cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2005 Plan vest at the rate specified by the plan administrator.
 
Generally, the plan administrator determines the term of stock options granted under the 2005 Plan, up to a maximum of ten years (except in the case of some incentive stock options, as described below). Unless the terms of an optionee’s stock option agreement provide otherwise, if an optionee’s service relationship with us, or any of our affiliates, ceases for any reason other than disability, death or following a change in control, the optionee may exercise any vested options for a period of three months following the cessation of service. If an optionee’s service relationship with us, or any of our affiliates, ceases due to disability or death (or an optionee dies within a specified period following cessation of service), the optionee or a beneficiary may exercise any vested options for a period of


13


Table of Contents

12 months, in the event of disability, and 18 months, in the event of death. In no event, however, may an option be exercised beyond the expiration of its term.
 
Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the plan administrator and may include (i) cash or check, (ii) a broker-assisted cashless exercise, (iii) the tender of common stock previously owned by the optionee, (iv) a net exercise of the option, (v) a deferred payment arrangement, and (vi) other legal consideration approved by the plan administrator.
 
Unless the plan administrator provides otherwise, options generally are not transferable except by will, the laws of descent and distribution, or pursuant to a domestic relations order. An optionee may designate a beneficiary, however, who may exercise the option following the optionee’s death.
 
Tax Limitations on Incentive Stock Option Grants.  Incentive stock options may be granted only to our employees. The aggregate fair market value, determined at the time of grant, of shares of our common stock with respect to incentive stock options that are exercisable for the first time by an optionee during any calendar year under all of our stock plans may not exceed $100,000. No incentive stock option may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our affiliates unless the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant and the term of the incentive stock option does not exceed five years from the date of grant.
 
 
The purchase price for stock purchase awards will not be less than the par value of our common stock. The purchase price for a stock purchase award may be payable:
 
  •  in cash or by check;
 
  •  according to a deferred payment arrangement; or
 
  •  in consideration of the recipient’s past or future services performed for us or our affiliates.
 
Shares of our common stock acquired under a stock purchase award may, but need not, be subject to a share repurchase option in our favor in accordance with a vesting schedule to be determined by the plan administrator. Rights to acquire shares under a stock purchase award may be transferred only upon such terms and conditions as set by the plan administrator.
 
 
A stock bonus award may be granted in consideration for the recipient’s past or future services performed for us or our affiliates or any other form of legal consideration. Shares of our common stock acquired under a stock bonus award may, but need not, be subject to forfeiture to us in accordance with a vesting schedule to be determined by the plan administrator. Rights to acquire shares under a stock bonus award may be transferred only upon such terms and conditions as set by the plan administrator.
 
 
Payment of any purchase price may be made in any form permitted under applicable law; however, we will settle a payment due to a recipient of a stock unit award by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the stock unit award agreement. Additionally, dividend equivalents may be credited in respect to shares covered by a stock unit award. Except as otherwise provided in the applicable award agreement, stock units that have not vested will be forfeited upon the participant’s cessation of continuous service for any reason.
 
 
The plan administrator determines the strike price for a stock appreciation right. Upon the exercise of a stock appreciation right, we will pay the participant an amount equal to the product of (i) the excess of the per share fair


14


Table of Contents

market value of our common stock on the date of exercise over the strike price, multiplied by (ii) the number of shares of common stock with respect to which the stock appreciation right is exercised. A stock appreciation right granted under the 2005 Plan vests at the rate specified in the stock appreciation right agreement as determined by the plan administrator.
 
The plan administrator determines the term of stock appreciation rights granted under the 2005 Plan. If a participant’s service relationship with us, or any of our affiliates, ceases, then the participant, or the participant’s beneficiary, may exercise any vested stock appreciation right for three months (or such longer or shorter period specified in the stock appreciation right agreement) after the date such service relationship ends. In no event, however, may an option be exercised beyond the expiration of its term.
 
 
The plan administrator may grant other awards related to our common stock. The plan administrator will set the number of shares under the award, the purchase price, if any, the timing of exercise and vesting and any repurchase rights associated with such awards.
 
 
In the event that there is a specified type of change in our capital structure, such as a merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other transaction not involving the receipt of consideration by us, appropriate adjustments will be made to:
 
  •  the number of shares reserved under the 2005 Plan;
 
  •  the maximum number of shares by which the share reserve may increase automatically each year;
 
  •  the maximum number of appreciation-only stock awards that can be granted in a calendar year; and
 
  •  the number of shares and exercise price or strike price, if applicable, of all outstanding stock awards.
 
 
In the event of specified significant corporate transactions, such as a sale of all or substantially all of our assets, a sale of at least 90% of our outstanding securities, a merger in which we are not the surviving entity, or a merger in which we are the surviving entity but our common stock outstanding immediately prior to the transaction is exchanged or converted into other property, all outstanding stock awards under the 2005 Plan may be assumed, continued or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to assume, continue or substitute for such stock awards, then:
 
  •  with respect to any such stock awards that are held by individuals whose service with us or our affiliates has not terminated more than three months prior to the effective date of the corporate transaction, the vesting and exercisability provisions of such stock awards will be accelerated in full and such awards will be terminated if not exercised prior to the effective date of the corporate transaction; and
 
  •  all other outstanding stock awards will terminate if not exercised prior to the effective date of the corporate transaction.
 
Our Board may also provide that the holder of an outstanding stock award not assumed in the corporate transaction will surrender such stock award in exchange for a payment equal to the excess of (i) the value of the property that the optionee would have received upon exercise of the stock award, over (ii) the exercise price otherwise payable in connection with the stock award.
 
 
Our Board has the discretion to provide that a stock award under the 2005 Plan will immediately vest as to all or any portion of the shares subject to the stock award (i) immediately upon the occurrence of specified change-in-control transactions, whether or not such stock award is assumed, continued or substituted by a surviving


15


Table of Contents

or acquiring entity in the transaction, or (ii) in the event a participant’s service with us or a successor entity is terminated actually or constructively within a designated period following the occurrence of specified change in control transactions. Stock awards held by participants under the 2005 Plan will not vest on such an accelerated basis unless specifically provided by the participant’s applicable award agreement.
 
 
The following is a summary of the principal U.S. federal income taxation consequences to participants and us with respect to participation in the 2005 Plan. This summary is not intended to be exhaustive, and does not discuss the income tax laws of any city, state or foreign jurisdiction in which a participant may reside.
 
Incentive Stock Options.  Incentive stock options granted under the 2005 Plan are intended to qualify for the favorable federal income tax treatment accorded “incentive stock options” under the Code. There generally are no federal income tax consequences to the participant or us by reason of the grant or exercise of an incentive stock option. However, the exercise of an incentive stock option may increase the participant’s alternative minimum tax liability, if any.
 
If a participant holds stock acquired through exercise of an incentive stock option for more than two years from the date on which the option was granted and more than one year after the date the option was exercised for those shares, any gain or loss on a disposition of those shares (a “qualifying disposition”) will be a long-term capital gain or loss. Upon such a qualifying disposition, we will not be entitled to any income tax deduction.
 
Generally, if the participant disposes of the stock before the expiration of either of those holding periods (a “disqualifying disposition”), then at the time of disposition the participant will realize taxable ordinary income equal to the lesser of (i) the excess of the stock’s fair market value on the date of exercise over the exercise price, or (ii) the participant’s actual gain, if any, on the purchase and sale. The participant’s additional gain or any loss upon the disqualifying disposition will be a capital gain or loss, which will be long-term or short-term depending on whether the stock was held for more than one year.
 
To the extent the participant recognizes ordinary income by reason of a disqualifying disposition, generally we will be entitled (subject to the requirement of reasonableness, the provisions of Section 162(m) of the Code, and the satisfaction of a tax reporting obligation) to a corresponding income tax deduction in the tax year in which the disqualifying disposition occurs.
 
Nonstatutory Stock Options.  No taxable income is recognized by a participant upon the grant of a nonstatutory stock option. Upon exercise of a nonstatutory stock option, the participant will recognize ordinary income equal to the excess, if any, of the fair market value of the purchased shares on the exercise date over the exercise price paid for those shares. Generally, we will be entitled (subject to the requirement of reasonableness, the provisions of Section 162(m) of the Code, and the satisfaction of a tax reporting obligation) to an income tax deduction in the tax year in which such ordinary income is recognized by the participant.
 
Upon disposition of the stock, the participant will recognize a capital gain or loss equal to the difference between the selling price and the sum of the amount paid for such stock plus any amount recognized as ordinary income upon acquisition of the stock. Such gain or loss will be long-term or short-term depending on whether the stock was held for more than one year.
 
Stock Purchase Awards and Stock Bonus Awards.  Upon receipt of a stock purchase award or stock bonus award, the participant will recognize ordinary income equal to the excess, if any, of the fair market value of the shares on the date of issuance over the purchase price, if any, paid for those shares. We will be entitled (subject to the requirement of reasonableness, the provisions of Section 162(m) of the Code, and the satisfaction of a tax reporting obligation) to a corresponding income tax deduction in the year in which such ordinary income is recognized by the participant.
 
However, if the shares issued upon the grant of a stock purchase award or stock bonus award are unvested and subject to repurchase by us in the event of the participant’s termination of service prior to vesting in those shares, the participant will not recognize any taxable income at the time of issuance, but will have to report as ordinary income, as and when our repurchase right lapses, an amount equal to the excess of (i) the fair market value of the shares on


16


Table of Contents

the date the repurchase right lapses, over (ii) the purchase price, if any, paid for the shares. The participant may, however, elect under Section 83(b) of the Code to include as ordinary income in the year of issuance an amount equal to the excess of (i) the fair market value of the shares on the date of issuance, over (ii) the purchase price, if any, paid for such shares. If the Section 83(b) election is made, the participant will not recognize any additional income as and when the repurchase right lapses. Both we and the participant will be required to satisfy certain tax withholding requirements applicable to such income. We will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time the shares are issued. In general, the deduction will be allowed for the taxable year in which such ordinary income is recognized by the participant.
 
Upon disposition of the stock acquired upon the receipt of a stock purchase award or stock bonus award, the participant will recognize a capital gain or loss equal to the difference between the selling price and the sum of the amount paid for such stock plus any amount recognized as ordinary income upon issuance (or vesting) of the stock. Such gain or loss will be long-term or short-term depending on whether the stock was held for more than one year.
 
Stock Unit Awards.  No taxable income is recognized upon receipt of a stock unit award. In general, the participant will recognize ordinary income in the year in which the shares subject to that unit vest and are actually issued to the participant in an amount equal to the fair market value of the shares on the date of issuance. We will be entitled (subject to the requirement of reasonableness, the provisions of Section 162(m) of the Code, and the satisfaction of a tax reporting obligation) to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time the shares are issued. In general, the deduction will be allowed for the taxable year in which such ordinary income is recognized by the participant.
 
Stock Appreciation Rights.  No taxable income is realized upon the receipt of a stock appreciation right. Upon exercise of the stock appreciation right, the fair market value of the shares (or cash in lieu of shares) received is recognized as ordinary income to the participant in the year of such exercise. Generally, with respect to employees, we are required to withhold from the payment made on exercise of the stock appreciation right or from regular wages or supplemental wage payments an amount based on the ordinary income recognized. Generally, we will be entitled (subject to the requirement of reasonableness, the provisions of Section 162(m) of the Code, and the satisfaction of a tax reporting obligation), to an income tax deduction in the year in which such ordinary income is recognized by the participant.
 
Potential Limitation on Deductions.  Section 162(m) of the Code denies a deduction to any publicly-held corporation for compensation paid to certain “covered employees” in a taxable year to the extent that compensation to each covered employee exceeds $1 million. It is possible that compensation attributable to awards, when combined with all other types of compensation received by a covered employee from us, may cause this limitation to be exceeded in any particular year. However, certain kinds of compensation, including qualified “performance-based compensation,” are disregarded for purposes of the deduction limitation.
 
In accordance with Treasury Regulations issued under Section 162(m) of the Code, compensation attributable to stock options and stock appreciation rights will qualify as performance-based compensation if (i) such awards are granted by a compensation committee or committee of our Board comprised solely of “outside directors,” (ii) the plan contains a per-employee limitation on the number of shares for which such awards may be granted during a specified period, (iii) the per-employee limitation is approved by the stockholders, and (iv) the exercise or strike price of the award is no less than the fair market value of the stock on the date of grant. It is intended that all options and stock appreciation rights granted with an exercise or strike price at least 100% of the fair market value of the stock subject to the option or stock appreciation right on the date of grant qualify as performance-based compensation that is exempt from the $1 million deduction limitation. Compensation attributable to stock bonus awards and stock unit awards under the 2005 Plan will not qualify as performance-based compensation, and therefore it remains subject to the $1 million deduction limitation.


17


Table of Contents

 
 
The following table provides certain information with respect to all of our equity compensation plans in effect as of the June 30, 2008.
 
 
                         
                Number of Securities
 
                Remaining Available for
 
    Number of Securities to be
    Weighted-Average
    Issuance Under Equity
 
    Issued Upon Exercise of
    Exercise Price of
    Compensation Plans
 
    Outstanding Options,
    Outstanding Options,
    (Excluding Securities
 
    Warrants and Rights
    Warrants and Rights
    Reflected in Column (a))
 
Plan Category
  (a)     (b)     (c)  
 
Equity compensation plans approved by security holders     1,334,132     $ 5.10       470,355  
                         
Equity compensation plans not approved by security holders                  
                         
Total
    1,334,132     $ 5.10       470,335  
                         
 
The Board Of Directors Recommends
A Vote In Favor Of Proposal 2.


18


Table of Contents

 
Security Ownership Of
Certain Beneficial Owners And Management
 
The following table sets forth certain information regarding the ownership of our common stock as of July 15, 2008 by:
 
  •  each director;
 
  •  each of the executive officers named in the Summary Compensation Table below;
 
  •  all of our directors and executive officers as a group; and
 
  •  all those known by us to be beneficial owners of more than five percent of our common stock.
 
Beneficial ownership is determined in accordance with the rules promulgated by the SEC and generally includes voting or investment power with respect to securities as well as shares of common stock subject to options exercisable within 60 days after July 15, 2008. Unless otherwise indicated, the address of each of the individuals listed below is c/o Cardica, Inc., 900 Saginaw Drive, Redwood City, California 94063.
 
                 
    Beneficial Ownership(1)  
    Number of
    Percent of
 
Beneficial Owner
  Shares     Total  
 
5% or Greater Stockholders:
               
Entities and Persons Affiliated with Allen & Company Incorporated
711 Fifth Avenue
New York, NY 10022
    1,189,946 (2)     7.46 %
Entities and Persons Affiliated with Sutter Hill Ventures
755 Page Mill Road, Suite A 200
Palo Alto, CA 94304-1005
    1,146,844 (3)     7.22 %
Named Executive Officers and Directors:
               
Bernard A. Hausen, M.D., Ph.D. 
    680,469 (4)     4.25 %
Doug T. Ellison
    158,395 (5)     1.00 %
Robert Y. Newell, IV
    121,039 (6)     *  
Bryan D. Knodel
    128,221 (7)     *  
J. Michael Egan
    239,243 (8)     1.52 %
Kevin T. Larkin
    36,891 (9)     *  
Richard P. Powers
    21,666 (10)     *  
Jeffrey Purvin
    14,666 (11)     *  
Richard M. Ruedy
    23,207 (12)     *  
Robert C. Robbins, M.D. 
    83,332 (13)     *  
John Simon, Ph.D. 
    704,599 (14)     4.43 %
Stephen A. Yencho, Ph.D. 
    559,138 (15)     3.54 %
William H. Younger , Jr. 
    1,146,844 (3)     7.22 %
All executive officers and directors as a group
    3,917,890 (16)     23.54 %
 
 
* Less than one percent.
 
(1) This table is based upon information provided to us by our officers, directors and certain principal stockholders and upon information about certain principal stockholders known to us based on a Schedules 13G filed with the SEC. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, we believe that each of the stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned. Applicable percentages are based on 15,788,613 shares outstanding on July 15, 2008, adjusted as required by rules promulgated by the SEC.
 
(2) Consists of (a) 417,938 shares held by Allen & Company Incorporated, (b) warrants to purchase 80,596 shares held by Allen & Company Incorporated that are exercisable within 60 days after July 15, 2008,


19


Table of Contents

(c) 40,556 shares held by Herbert A. Allen, (d) 96,988 shares held by Susan Allen, (e) warrants to purchase 24,225 shares of common stock held by Susan Allen that are exercisable within 60 days after July 15, 2008, (f) 284,818 shares held by Bruce Allen (g) warrants to purchase 38,760 shares of common stock held by Bruce Allen that are exercisable within 60 days after July 15, 2008, (h) 176,840 shares held by John Simon, one of our directors, (i) warrants to purchase 24,225 shares held by John Simon and (j) 5,000 shares subject to stock options exercisable within 60 days after July 15, 2008 held by John Simon. Allen & Company Incorporated disclaims beneficial ownership of the shares described in (c) through (j).
 
(3) Consists of (a) 858,763 shares of common stock held by Sutter Hill Ventures LP, a California limited partnership (“Sutter Hill Ventures”), (b) warrants to purchase 70,496 shares of common stock held by Sutter Hill Ventures that are exercisable within 60 days after July 15, 2008, (c) 9,726 shares held by Sutter Hill Entrepreneurs Fund (AI), L.P. (“SHAI”), (d) warrants to purchase 797 shares of common stock held by SHAI that are exercisable within 60 days after July 15, 2008, (e) 24,628 shares held by Sutter Hill Entrepreneurs Fund (QP), L.P. (“SHQP”), (f) warrants to purchase 2,019 shares of common stock held by SHQP that are exercisable within 60 days after July 15, 2008, (g) 7,333 shares subject to stock options exercisable within 60 days after July 15, 2008 held by William H. Younger, Jr., one of our directors, (h) 137,535 shares held by William H. Younger, Jr., Trustee, The Younger Living Trust U/ A/ D 1/20/95, (i) warrants to purchase 13,385 shares of common stock held by William H. Younger, Jr., Trustee, The Younger Living Trust U/ A/ D 1/20/95 that are exercisable within 60 days after July 15, 2008, (j) 19,782 shares held by SHV Profit Sharing Plan, a retirement trust, for the benefit of Mr. Younger and (k) 2,380 shares held by Mr. Younger’s children, for which Mr. Younger disclaims beneficial ownership. Mr. Younger has shared voting and dispositive power with respect to the shares held by Sutter Hill Ventures, SHAI, SHQP, William H. Younger, Jr., Trustee, The Younger Living Trust U/ A/ D 1/20/95 and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest in such shares.
 
(4) Includes 213,434 shares subject to stock options that are exercisable within 60 days after July 15, 2008.
 
(5) Includes 118,395 shares subject to stock options that are exercisable within 60 days after July 15, 2008.
 
(6) Consists of (a) 46,666 shares held by Robert Y. Newell IV, (b) 2,333 shares held by Robert Y. Newell and Ethel N. Newell, Trustees, Newell Family 1999 Trust UA Dated 10/12/99, and (c) 72,040 shares subject to stock options that are exercisable within 60 days after July 15, 2008.
 
(7) Includes 110,654 shares subject to stock options that are exercisable within 60 days after July 15, 2008.
 
(8) Includes 5,000 shares subject to stock options and warrants to purchase 2,423 shares of common stock that are exercisable within 60 days after July 15, 2008.
 
(9) Includes 18,333 shares subject to stock options that are exercisable within 60 days after July 15, 2008.
 
(10) Includes 18,333 shares subject to stock options that are exercisable within 60 days after July 15, 2008.
 
(11) Includes 11,666 shares subject to stock options that are exercisable within 60 days after July 15, 2008.
 
(12) Consists of 23,207 shares subject to stock options that are exercisable within 60 days after July 15, 2008.
 
(13) Includes 53,332 shares subject to stock options that are exercisable within 60 days after July 15, 2008.
 
(14) Consists of (a) 417,938 shares held by Allen & Company Incorporated, (b) warrants to purchase 80,596 shares held by Allen & Company Incorporated that are exercisable within 60 days after July 15, 2008, (c) 176,840 shares held by John Simon (d) warrants to purchase 24,225 shares held by John Simon and (e) 5,000 shares subject to stock options exercisable within 60 days after July 15, 2008 held by John Simon.
 
(15) Includes 5,000 shares subject to stock options that are exercisable within 60 days after July 15, 2008.
 
(16) Includes 661,727 shares subject to stock options and warrants to purchase 193,941 shares of common stock beneficially owned by all executive officers and directors that are exercisable within 60 days after July 15, 2008.
 
 
Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our directors and executive officers, and persons who own more than ten percent of a registered class of our equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity


20


Table of Contents

securities. Our executive officers, directors and greater than ten percent stockholders are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file.
 
To our knowledge, based solely on a review of the copies of such reports furnished to us and written representations that no other reports were required, during fiscal 2008, our executive officers, directors and greater than ten percent beneficial owners complied with all Section 16(a) filing requirements applicable to each of them, respectively.
 
AUDIT COMMITTEE AND INDEPENDENT AUDITOR INFORMATION
 
Report of the Audit Committee of the Board of Directors*
 
 
The Audit Committee has reviewed and discussed the Company’s audited financial statements for the fiscal year ended June 30, 2008 with management. In addition, the Audit Committee has discussed with Ernst & Young LLP, the Company’s independent registered public accounting firm, the matters required to be discussed by Statement on Auditing Standards No. 61, as amended, “Communications with Audit Committees,” as adopted by the Public Company Accounting Oversight Board in Rule 3200T. The Audit Committee has also received the written disclosures and the letter from the independent accountants required by applicable requirements of the Public Company Accounting Oversight Board regarding the independent accountants’ communications with the audit committee concerning independence, and has discussed with the independent accountants the independent accountants’ independence.
 
 
Based on the foregoing, the Audit Committee unanimously recommended to the Company’s Board that the Company’s audited financial statements for the fiscal year ended June 30, 2008 be included in its Annual Report on Form 10-K for the fiscal year ended June 30, 2008.
 
AUDIT COMMITTEE
 
Richard P. Powers, Chair
J. Michael Egan
William H. Younger, Jr.
 
 
   * The material in this report is not “soliciting material,” is not deemed “filed” with the SEC, and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language contained in such filing.


21


Table of Contents

 
 
In connection with the audit of our fiscal year 2008 and 2007 financial statements, we entered into an engagement agreement with Ernst & Young LLP, which set forth the terms by which Ernst & Young LLP will perform audit services for us. That agreement is subject to alternative dispute resolution procedures and an exclusion of punitive damages.
 
The following table represents aggregate fees billed to us for fiscal 2008 and 2007 by Ernst & Young LLP.
 
                 
    Fiscal Year Ended
 
    June 30,  
    2008     2007  
 
Audit Fees
  $ 764,900     $ 351,500  
Audit-related Fees
           
Tax Fees
  $ 80,000        
All Other Fees
           
                 
Total Fees
  $ 844,900     $ 351,500  
                 
 
Our Audit Committee has pre-approved all services provided by Ernst & Young LLP for the fiscal year ended June 30, 2008. In the above table, “audit fees” are fees we paid Ernst & Young LLP for professional services for the audit of our financial statements included in Form 10-K and review of financial statements included in Form 10-Qs, and for services that are normally provided by Ernst & Young LLP in connection with statutory and regulatory filings.
 
 
The Audit Committee pre-approves all audit and non-audit services rendered by our independent registered public accounting firm, Ernst & Young LLP. Pre-approval also may be given as part of the Audit Committee’s approval of the scope of the engagement of the independent registered public accounting firm or on an individual explicit case-by-case basis before the independent registered public accounting firm is engaged to provide each service. The Audit Committee Charter permits the Audit Committee to delegate pre-approval authority to one or more individuals, such authority having been duly delegated to Mr. Powers, provided that Mr. Powers report any such pre-approvals to the full Audit Committee at its next scheduled meeting.


22


Table of Contents

 
Proposal 3
 
RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED
 
The Audit Committee of the Board has selected Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2009 and has further directed that management submit the selection of the independent registered public accounting firm for ratification by the stockholders at the annual meeting. Ernst & Young LLP has audited our financial statements since our inception in 1997. Representatives of Ernst & Young LLP are expected to be present at the annual meeting. They will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions.
 
Neither our Bylaws nor other governing documents or law require stockholder ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm. However, the Audit Committee of the Board is submitting the selection of Ernst & Young LLP to the stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit Committee of the Board will reconsider whether to retain that firm. Even if the selection is ratified, the Audit Committee of the Board in its discretion may direct the appointment of a different independent registered public accounting firm at any time during the year if they determine that such a change would be in our best interest and in the best interests of our stockholders.
 
The affirmative vote of the holders of a majority of the shares present in person or represented by proxy at the annual meeting regarding Proposal No. 3 will be required to ratify the selection of Ernst & Young LLP. Abstentions will be counted toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as negative votes. Broker non-votes are counted towards a quorum, but are not counted for any purpose in determining whether this matter has been approved.
 
The Board Of Directors Recommends
A Vote In Favor Of Proposal 3.


23


Table of Contents

 
Executive Compensation
 
Compensation Discussion and Analysis
 
 
Cardica is a medical device company that has been undergoing a transition from the development stage to product commercialization. We design and manufacture automated anastomosis systems for coronary artery bypass graft surgery. Our C-Port® Distal Anastomosis Systems are marketed in Europe and the United States. The PAS-Port® Proximal Anastomosis System is marketed in Europe and Japan, and during fiscal 2008 we submitted a 510(k) application to the U.S. Food & Drug Administration (the “FDA”) for clearance of the PAS-Port system. We obtained FDA clearance of our PAS-Port system in September 2008. We are also developing additional devices to facilitate vascular and other surgical procedures. The success of earlier-stage medical device companies is significantly influenced by the quality of their work force, and we face significant competition for executives and other talented employees from the numerous medical device and other technology companies in the San Francisco Bay Area. In light of these circumstances, our compensation program is designed to help us attract, reward and retain employees who contribute to our success and to provide substantial alignment of management’s interests with the long-term interests of stockholders.
 
We pay cash compensation to provide an appropriate and competitive level of current cash income and to reward, in the case of any bonus or base salary increase, strong performance over the past year. We also offer long-term incentive compensation. As discussed in further detail below, our fiscal 2008 compensation program for our named executive officers consisted of, and was intended to strike a balance among, the following three primary components, which were also the primary components of executive compensation for the last several years:
 
  •  Base Salary.  Base salary for each of our named executive officers is based principally on an evaluation of individual job performance during the prior year, as well as base salary benchmarking against comparable companies.
 
  •  Performance Bonus.  Annual cash bonuses are intended to align our named executive officers’ compensation with our business objectives and performance and with the interests of our stockholders and to enable us to retain and reward named executive officers who demonstrate strong performance. Named executive officer performance bonuses take into account corporate goals approved by our Board and each named executive officer’s performance.
 
  •  Long-Term Incentive Compensation.  Long-term incentive awards, comprised of stock option grants and/or restricted stock grants, are designed to ensure that incentive compensation is linked to the long-term performance of our common stock and to align our named executive officers’ performance objectives with the interests of our stockholders. Stock options and restricted stock are granted to our named executive officers both as a reward for past individual and corporate performance and as an incentive for future performance.
 
 
The Compensation Committee of our Board acts on behalf of the Board in fulfilling the Board’s responsibilities to oversee our compensation policies, plans and programs and review and determine the compensation to be paid to our executive officers and directors. The Compensation Committee is comprised entirely of independent directors who are not officers or employees. The Compensation Committee is comprised of Messrs. Purvin and Larkin and Dr. Robbins.
 
The Compensation Committee attempts to:
 
  •  offer compensation opportunities that attract and retain executives whose abilities are critical to our long-term success, motivate individuals to perform at their highest level and reward outstanding achievement; and
 
  •  maintain a significant portion of the executives’ total compensation at risk, tied to achievement of financial, organizational and management performance goals.


24


Table of Contents

 
The responsibilities of the Compensation Committee include the following:
 
  •  reviewing, modifying (as needed) and approving our overall compensation strategy and policies, including reviewing and approving corporate performance goals and objectives relevant to the compensation of our executive officers, evaluating and recommending to the Board for approval the compensation plans and programs advisable for us and the modification or termination thereof, establishing policies with respect to equity compensation arrangements and reviewing and approving the terms of any employment agreements, severance arrangements, change-of-control protections and any other compensatory arrangements for our executive officers;
 
  •  recommending to the Board for determination and approval the compensation and other terms of employment of our Chief Executive Officer and evaluating our Chief Executive Officer’s performance in light of relevant corporate performance goals and objectives;
 
  •  reviewing and approving the individual and corporate performance goals and objectives of our other executive officers and recommending to the Board for determination and approval the compensation and other terms of employment of these executive officers, taking into consideration each of the executive officers’ success in achieving his or her individual performance goals and objectives and the corporate performance goals and objectives deemed relevant to each officer as established by the Committee;
 
  •  reviewing and recommending to the Board the type and amount of compensation to be paid or awarded to Board members, including consulting, retainer, Board meeting, committee and committee chair fees and stock option grants or awards; and
 
  •  recommending to the Board the adoption, amendment and termination of our stock option plans, bonus plans, stock purchase plans and similar programs and administering these plans.
 
In performing its duties, the Compensation Committee considers such matters as it deems appropriate, including our financial and operating performance, the alignment of the interests of our executive officers and stockholders, compensation at companies that the Compensation Committee considers to be comparable to us and our ability to attract and retain qualified individuals. For executive compensation decisions, including decisions relating to the grant of stock options to executive officers, the Compensation Committee typically considers the recommendations of Dr. Hausen, our Chief Executive Officer, with respect to other executive officers. While Dr. Hausen did not participate in the Compensation Committee’s deliberations about executive compensation matters in or with respect to fiscal 2008, he did participate in discussions among the full Board regarding compensation matters in or with respect to fiscal 2008 for executives other than himself. Dr. Hausen also annually leads the development of our corporate goals, which are reviewed by the Compensation Committee and the Board, and, subject to their input, approved by the Board. In determining his named executive officer compensation recommendations, Dr. Hausen solicits the input of, and receives documentary support from, our Human Resources group and a human resources consultant. The Compensation Committee also receives documentary and analysis support from our Human Resources group, a human resources consultant and our Chief Financial Officer. Other than Dr. Hausen and Robert Newell, our Chief Financial Officer, no other executive officers participated in the determination or recommendation of the amount or form of named executive officer compensation in or with respect to fiscal 2008. The Compensation Committee does not delegate any of its functions to others in determining executive compensation.
 
The Compensation Committee has not adopted any formal policies or guidelines for allocating compensation between current and long-term incentive compensation, or between cash and non-cash compensation; however, the Compensation Committee has commenced relying significantly upon external data and its general goal to align our executive officer’s compensation with that of approximately the mean of the comparable companies evaluated, as described more fully below under the heading “Compensation Benchmarking”. However, because of the overall importance to our success of aggressively pursuing our strategic goals, as well as to preserve our cash resources, a significant portion of our named executive officers’ total compensation has been, and is expected to continue to be, comprised of stock options. In determining the amount and mix of compensation elements and whether each element provides the correct incentives and rewards for performance consistent with our short and long-term goals and objectives, the Compensation Committee relies on its judgment about each individual and other factors rather


25


Table of Contents

than adopting a formulaic approach to compensatory decisions that are narrowly responsive to short-term changes or evolution in business performance.
 
 
The Compensation Committee believes that it is important when making compensation decisions to be informed as to the current practices of comparable publicly-held companies. To this end, to inform the Compensation Committee’s recommendations with respect to named executive officer base salaries for fiscal 2008, the Compensation Committee requested that our Human Resources group or Chief Financial Officer provide a review of Cardica’s base salaries for executive officers as compared to a peer group of companies of a size and complexity similar to ours. This review also included information with respect to bonuses and stock option awards that the Compensation Committee used in determining bonus and stock option awards for fiscal 2008 and prior performance. In June 2007, our Chief Financial Officer provided to the Compensation Committee a benchmarking survey comprised of the following component companies: Xtent, Inc., Atricure Inc., Hansen Medical Inc., Cryocor Inc., Endologix Inc., Hemosense Inc., Micrus Endovascular Corp. and Vnus Medical Technologies Inc. These companies were selected based on market capitalization, position in medical device industry and revenue stage.
 
To inform the Compensation Committee’s recommendations with respect to named executive officer base salaries for fiscal 2009 and bonus and stock option awards for fiscal 2008 performance, the Compensation Committee requested that our Human Resources group and a human resources consultant, Remedy Compensation Consulting, retained by us to provide an analysis of our base salaries, bonuses and stock option awards for executive officers as compared to a peer group of companies of a size and complexity similar to that of Cardica. We also requested that the consultant review and analyze the bonus plan for Mr. Ellison. In June 2008, our Human Resources group and the human resources consultant provided to the Compensation Committee a benchmarking survey comprised the following component companies, as approved by our Compensation Committee: Alphatec Holdings Inc., Atricure Inc., ATS Medical, Inc., Biolase technology, Inc., Bovie Medical Corporation, BSD Medical Corporation, Cambridge Heart, inc., CardioDynamics International Corp., Endologix Inc., Hansen Medical Inc., LeMaitre Vascular, Inc., Micrus Endovascular Corp., NMT Medical, Power Medical Interventions, Inc., Steriotaxis, Inc., Strategic Diagnostics, Inc., ThermoGenesis Corp., Vascular Solutions, Inc. and Xtent, Inc. These companies were selected based on market capitalization, position in medical device industry and revenue stage.
 
The Compensation Committee realizes that benchmarking our executive compensation program against compensation earned at comparable companies is generally not appropriate as a stand-alone tool for setting compensation due to the aspects of our business and objectives that are unique to us. However, the Compensation Committee generally believes that gathering this information is an important part of its decision-making process with respect to our executive compensation program. The Compensation Committee generally targets approximately the benchmark group mean for compensation of our executives, though the Compensation Committee uses its discretion to determine whether to be above or below the mean and to adjust short- and long-term incentives as it deems appropriate.
 
In addition to compensation benchmarking data, the Compensation Committee has historically taken into account input from other sources, including input from other independent members of the Board and publicly available data relating to the compensation practices and policies of other medical device companies. In recommending named executive officer base salaries for fiscal 2008 and 2009 and bonus and stock option awards for fiscal 2008 performance, the Compensation Committee also considered Dr. Hausen’s recommendations with respect to other named executive officers.
 
 
Our annual cash bonuses are intended to align our named executive officers’ compensation with our business objectives and performance and with the interests of our stockholders and to enable us to retain and reward named executive officers who demonstrate strong performance. Annual cash bonuses are discretionary, but the Compensation Committee follows guidelines that set bonus targets (expressed as a percentage of base salary) based on the applicable position and take into account the achievement of company-wide objectives and individual performance. The bonus targets are reviewed annually by the Board and Compensation Committee. The


26


Table of Contents

Compensation Committee follows guidelines with respect to the portions of each named executive officer’s total bonus target that are tied to the company-wide and individual performance. Whether or not a bonus is paid for any year is within the discretion of the Board. The actual bonus awarded in any year, if any, may be more or less than the targets, depending on individual performance and the achievement of company-wide objectives. The Compensation Committee retains the discretion to increase, reduce or eliminate the bonus award that otherwise might be payable to any individual based on actual performance as compared to the individual’s pre-established bonus target, and to pay bonuses even if certain corporate goals or individual performance objectives are not met.
 
The Compensation Committee has not determined whether it would attempt to recover bonuses from our named executive officers if the performance objectives that led to a bonus determination were to be restated, or found not to have been met to the extent originally believed by the Compensation Committee.
 
Our Vice President of Worldwide Sales and Marketing is not eligible for the bonus program described above; rather, Mr. Ellison has a separate bonus plan tied to sales. Under Mr. Ellison’s bonus plan for fiscal 2008, Mr. Ellison was eligible to receive additional bonuses of up to $46,000 quarterly based upon our gross sales was eligible to receive additional amounts if the our sales exceeded our sales plan and for achieving certain objectives. Under Mr. Ellison’s bonus plan for fiscal 2009, Mr. Ellison is eligible to receive bonuses of up to $190,000 for fiscal year 2009, based upon a variable percentage of our net product sales. In addition, in the event that we exceed our net product sales plan for the year, Mr. Ellison is entitled to receive up to 6% of our net product sales over the net product sales contemplated by the sales plan. This amount is payable quarterly if our net product sales for the year to date exceed the net product sales contemplated by the sales plan for such period. The Compensation Committee decided to focus on aligning Mr. Ellison’s total compensation at approximately the benchmark group mean for his peers, in light of Mr. Ellison’s role in our sales force and his continued focus on achieving our sales objectives.
 
 
The three primary components of executive compensation in fiscal 2008 were base salaries, cash bonuses and grants of stock options.
 
 
Named executive officer base salaries were evaluated by the Compensation Committee in June 2007 for the remainder of fiscal 2007 and fiscal 2008 and in August 2008 for purposes of fiscal 2009. Base salaries for named executive officers were based principally on the Compensation Committee’s evaluation of individual performance, the Compensation Committee’s assessment of the base salaries paid by similar companies to executive officers holding equivalent positions and the appropriate amount of a cost of living adjustment, our cash resources and, with respect to named executive officers other than Dr. Hausen, recommendations made by the Human Resources group and Dr. Hausen. In setting fiscal 2008 and 2009 base salaries, the Compensation Committee neither based its considerations on any single factor nor did it specifically assign relative weights to factors, but rather it considered a mix of factors and evaluated individual performance against that mix both in absolute terms and in relation to other company executives. The Compensation Committee sought to pay cash compensation that is fair and competitive relative to the group of companies against which our compensation practices were benchmarked.
 
 
In February 2008, the Board adopted our Bonus Plan for fiscal 2008, which was administered by the Compensation Committee and applied to our named executive officers other than Mr. Ellison, as Mr. Ellison had a separate bonus plan, as described above. The Board set the target bonuses, prior to adopting the 2008 Bonus Plan, in the second fiscal quarter of fiscal 2008. The objectives of the 2008 Bonus Plan were to:
 
  •  provide an opportunity for an annual bonus based on our financial results;
 
  •  build stockholder value and create a win-win partnership between employees and Cardica;
 
  •  reward employees for overall company performance; and
 
  •  tie the incentive bonus to our performance for fiscal 2008.


27


Table of Contents

 
The Bonus Plan was intended to provide us with the following benefits:
 
  •  promote a better understanding of business goals and performance measures throughout our company;
 
  •  increase emphasis on performance;
 
  •  improved our ability to attract, motivate and retain employees;
 
  •  add incentive and focus on achieving our goals; and
 
  •  slow salary growth through more variable and performance-based compensation.
 
For fiscal 2008, each of our named executive officer’s bonus target, other than the bonus target for the Chief Executive Officer and our Vice President of Worldwide Sales and Marketing, was set at 25% of base salary. The bonus target with respect to the Chief Executive Officer was set at 50% of base salary based upon the Compensation Committee’s assessment of Dr. Hausen’s target total compensation relative to peers and its desire to appropriately tie Dr. Hausen’s compensation to our overall success. As described above, our Vice President of Worldwide Sales and Marketing was not eligible for a bonus under the 2008 Bonus Plan. For fiscal 2008, the 2008 Bonus Plan provided guidelines that 75% of each named executive officer’s total bonus target, other than for the Chief Executive Officer, was tied to the company-wide performance and 25% was tied to individual performance. For the Chief Executive Officer, target cash bonus amount were based 100% on achievement of corporate objectives. Our fiscal 2008 corporate goals approved by the Board for purposes of the Bonus Plan were:
 
  •  achieve product revenue of $5.1 million and total revenue of $8.0 million;
 
  •  complete the PAS-Port EPIC trial;
 
  •  obtain FDA clearance; of the PAS-Port
 
  •  complete Phase 1 of patent foramen ovale, or PFO, device development with Cook Incorporated;
 
  •  launch X-Port in Europe;
 
  •  commence IDE clinical trial for X-Port;
 
  •  obtain financing of at least $12 million;
 
  •  complete X-Port II development;
 
  •  establish C-Port Flex A as an enabling technology for minimally invasive CABG procedures;
 
  •  complete C-Port xChange development and launch C-Port xChange;
 
  •  complete C-Port xV development and launch C-Port xV;
 
  •  enter into a third corporate development contract; and
 
  •  complete prototype development of a new product.
 
Named executive officer performance bonuses for fiscal 2008 performance were generally determined in accordance with the criteria set forth under the 2008 Bonus Plan. In August 2008, the Compensation Committee determined that in fiscal 2008, Cardica had essentially achieved the following goals:
 
  •  achieved product revenue of $5.1 million and total revenue of $8.0 million;
 
  •  completed the PAS-Port EPIC trial;
 
  •  completed Phase 1 of PFO device development with Cook Incorporated;
 
  •  obtained financing of at least $12 million.
 
  •  completed X-Port II development;
 
  •  established C-Port Flex A as an enabling technology for minimally invasive CABG procedures;
 
  •  completed C-Port xChange development and launched C-Port xChange; and


28


Table of Contents

 
  •  completed C-Port xV development.
 
The Compensation Committee determined the following goals had not been achieved:
 
  •  obtain PAS-Port FDA clearance;
 
  •  launch X-Port in Europe;
 
  •  commence IDE clinical trial for X-Port;
 
  •  launch C-Port xV;
 
  •  enter into a third corporate development contract; and
 
  •  complete prototype development of a new product.
 
The Compensation Committee’s determination of cash bonuses for fiscal 2008 for the named executive officers, including our Chief Executive Officer, took into account its assessment of the company’s and each named executive officer’s performance and total compensation, the compensation of similarly situated executive officers at peer companies and other factors. Based upon its assessments described above as to our achievement of our company goals, the Compensation Committee determined that the company goals were 90% achieved.
 
While the Compensation Committee considered the general guidelines related to bonus target amounts and the portion of each named executive officer’s annual cash bonus that should be tied to company-wide and individual performance components, the Compensation Committee exercised discretion in determining the amount of cash bonuses for fiscal 2008 and did not attempt to precisely quantify the level of achievement of each of individual and corporate goals or to apply strict percentage criteria to an allocation of each named executive officer’s cash bonus between company-wide and individual performance components. Rather, the Compensation Committee determined the percentage of each officer’s target bonus that should be paid to the named executive officer based on a balancing of our company-wide performance and individual performance and an aggregate quantification of the percentage achievement.
 
In August 2008, our Board, upon recommendation of the Compensation Committee, adopted our 2009 bonus plan, within the framework described above, for our executive officers including target bonuses (as a percentage of base salary) for our named executive officers other than Douglas Ellison, our Vice President of Worldwide Sales and Marketing, whose bonus plan is described below. The bonus plan is designed to reward our executives for both personal and company-wide performance, based upon pre-established and communicated personal and company-wide goals, however, Dr. Hausen’s bonus is tied 100% to the achievement of company-wide goals. The target bonuses for our named executive officers, other than Mr. Ellison, for fiscal 2009 are 30% of base salary for each named executive officer other than our chief executive officer and 40% of base salary for our named executive officer. These target bonuses were designed to align total compensation of our named executive offers (other than Mr. Ellison) with approximately the mean of the benchmark group.
 
 
Long-term incentive awards, such as stock options, are designed to ensure that incentive compensation is linked to the long-term performance of Cardica common stock. Cardica has provided long-term compensation to certain members of senior management under our 2005 Plan. The 2005 Plan provides Cardica with the ability to periodically reward key employees, including named executive officers, with options to purchase shares of our common stock as well as other stock purchase rights. We generally grant options in lieu of other equity awards because the Compensation Committee believes the overall incentive value of stock options is higher than the overall incentive value of other equity awards and, further, that options align our interests with those of our executives. The size of the option grant is generally intended to reflect the named executive officer’s position with us and his or her individual job performance and contributions to our annual goals. A named executive officer’s option position is also considered in determining the size of the option grant. The value of stock options is tied to the future performance of our common stock and provides value to the recipient only when the price of our common stock increases above the option grant price. Through option grants and other stock awards, executives receive significant equity incentives to build long-term stockholder value. We do not time the granting of our stock option awards with


29


Table of Contents

any favorable or unfavorable news released by us, and the proximity of the grant of any awards to an earnings announcement or other market events is coincidental.
 
 
Under their individual agreements and the 2005 Plan, our named executive officers are entitled to certain severance and change of control benefits, the terms of which are further described in detail below under “Potential Payments Upon Termination or Change-in-Control”. In connection with a change of control transaction, 50% of the then-unvested shares subject to options held by the named executive officers will become immediately vested, and 100% of these shares will become vested if the named executive officer’s employment is terminated without cause or resigns for good reason in connection with a change of control transaction. These change of control benefits that are structured to include a “double-trigger” basis, meaning that before a named executive officer can receive accelerated vesting of all options: (1) a change of control must occur and (2) within one month prior to or 13 months following such change of control, the named executive officer’s employment must be terminated for good reason or without cause. These provisions were included to motivate our named executive officers to act in the best interests of our stockholders by removing the distraction of post-change of control uncertainties faced by the named executive officers with regard to their continued employment and compensation. We believe that double-trigger change of control severance compensation is attractive to maintain continuity and retention of key management personnel and is consistent with our compensation philosophy. We also believe that the other severance benefits offered to Dr. Hausen are appropriate, particularly with respect to a termination by us without cause since in that scenario, we and the named executive officer have a mutually-agreed-upon severance package that is in place prior to any termination event, which provides us with more flexibility to make a change in executive management if such a change is in the stockholders’ best interests.
 
 
We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by the Board. These agreements provide for indemnification for related expenses including attorneys’ fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe that indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain directors’ and officers’ liability insurance.
 
 
We maintain a 401(k) plan in which substantially all of our employees are entitled to participate. Employees contribute their own funds, as salary deductions, on a pre-tax basis. Contributions may be made up to plan limits, subject to government limitations. The 401(k) plan does not currently allow for matching contributions by us. We also provide medical, dental and life insurance benefits to all full-time employees, including our named executive officers.
 
 
The Compensation Committee recommended all of the named executive officers’ fiscal 2008 and 2009 base salaries, fiscal 2008 bonus and fiscal 2008 grants of restricted stock to the Board for approval, all of which were approved by the Board. Our key compensation actions for Dr. Hausen and the other named executive officers during and with respect to fiscal 2008 are summarized as follows:
 
 
For fiscal 2008, Dr. Hausen’s base salary was set at $312,700, or an approximately 6% increase from his prior year’s base salary of $295,000. The increase in Dr. Hausen’s fiscal 2008 base salary from fiscal 2007 was based on his overall performance as CEO, the Company’s regulatory and clinical progress during fiscal 2007, and his salary relative to peers at other public medical device companies. Dr. Hausen’s base salary for fiscal 2009 has been set at $350,000, or an approximately 12% increase from his fiscal 2008 base salary. The increase in Dr. Hausen’s fiscal 2009 base salary from fiscal 2008 was based on the Compensation Committee’s desire to align Dr. Hausen’s base


30


Table of Contents

salary with approximately the mean of the benchmark group for his peers. The Compensation Committee also considered its assessment of Dr. Hausen’s strong performance since the prior salary evaluation, including our achievements discussed above.
 
The Compensation Committee determined that Dr. Hausen should be rewarded based on 90% achievement of his 50% target bonus, taking into account Cardica’s achievements in fiscal 2008, as discussed above. The Compensation Committee determined that 90% achievement was appropriate we achieved a number of our corporate goals and the Compensation Committee believed, after evaluating all relevant factors, that our failure to achieve the other objectives was not reflective of any failure on the part of Dr. Hausen or our management to take all reasonable steps to achieve those goals. Accordingly, Dr. Hausen was awarded a cash bonus award under our 2008 Bonus Plan of $140,400 (90% of 50% of $312,700 base salary for fiscal 2008) as compensation for his performance in fiscal 2008.
 
Dr. Hausen did not receive any equity grants in fiscal 2008. In fiscal 2009, Dr. Hausen has been granted an option to purchase 85,000 shares of our common stock under the 2005 Plan. The option has an exercise price of $9.20 per share, which was the closing sales price of our common stock as quoted on the Nasdaq Global Select Market on the date of grant. The Compensation Committee determined that the option grant was appropriate to align Dr. Hausen’s annual target awards level with that of the benchmark group mean. The shares subject to the option vest at a rate of 1/48th per month following the date of grant, provided Dr. Hausen continues to provide services to the Company, and has accelerated vesting under certain circumstances as described under “Severance and Change of Control Benefits” above.
 
Dr. Hausen does not receive separate compensation for serving as a member of the Board.
 
 
For fiscal 2008, Mr. Ellison’s base salary was set at $201,400, or an approximately 6% increase from his fiscal 2007 base salary. The increase in Mr. Ellison’s fiscal 2008 base salary from fiscal 2007 was based on the same general factors considered in connection with the increase in Dr. Hausen’s base salary and the Compensation Committee’s assessment, based in part on Dr. Hausen’s assessment, of Mr. Ellison’s strong performance since the prior salary determination. Mr. Ellison’s base salary for fiscal 2009 has been set at $214,000, or an approximately 6% increase from his fiscal 2008 base salary. The increase in Mr. Ellison’s fiscal 2009 base salary from fiscal 2008 was based on the Compensation Committee’s assessment, based in part on Dr. Hausen’s assessment, of Mr. Ellison’s strong performance since the prior salary determination and on the Committee’s desire to align Mr. Ellison’s total cash compensation, when salary is taken together with his separate bonus plan, with the benchmark group mean.
 
Mr. Ellison was awarded a cash bonus award of $230,509 as compensation for his performance in fiscal 2008. Mr. Ellison’s bonus award was based on the terms of the separate bonus plan established for Mr. Ellison, described above. This amount was based upon our sales in fiscal 2008 and the terms of the bonus plan established for Mr. Ellison. Mr. Ellison is eligible for bonuses for fiscal 2009 under the separate bonus plan adopted for him and described above.
 
In fiscal 2008, Mr. Ellison was awarded 40,000 shares of common stock under the 2005 Plan (the “Stock Bonus”) as an additional incentive for Mr. Ellison to reemphasize our mid- and long-term objectives and align Mr. Ellison’s incentives therewith. One-fourth (1/4th) of the shares of common stock subject to the Stock Bonus vest on October 10th of each of 2008, 2009, 2010 and 2011, respectively, provided in each case that Mr. Ellison is then providing continuous service to Cardica (as defined in the 2005 Plan). The Stock Bonus is subject to accelerated vesting such that 50% of the then-unvested shares subject to the Stock Bonus shall become immediately vested upon a change in control, provided that Mr. Ellison is still providing service to Cardica at that time, and 100% of the shares subject to the Stock Bonus will immediately vest if Mr. Ellison is terminated without cause or resigns for good reason one month prior to or 13 months following the closing of a change in control.
 
In fiscal 2009, Mr. Ellison has been granted an option to purchase 25,000 shares of common stock under the 2005 Plan. The option has an exercise price of $9.20 per share, which was the closing sales price of our common stock as quoted on the Nasdaq Global Select Market on the date of grant. The Compensation Committee determined that the option grant was appropriate to align Mr. Ellison’s annual target awards level with that of the benchmark


31


Table of Contents

group mean. The shares subject to the option vest at a rate of 1/48th per month following the date of grant, provided Mr. Ellison continues to provide services to the Company, and has accelerated vesting under certain circumstances as described under “Severance and Change of Control Benefits” above.
 
 
For fiscal 2008, Dr. Knodel’s base salary was set at $243,800, or an approximately 6% increase from his fiscal 2008 base salary. The increase in Dr. Knodel’s fiscal 2008 base salary from fiscal 2007 was based on the same general factors considered in connection with the increase in Dr. Hausen’s base salary and the Compensation Committee’s assessment, based in part on Dr. Hausen’s assessment, of Dr. Knodel’s strong performance since the prior salary determination. Dr. Knodel’s base salary for fiscal 2009 has been set at $254,000, or an approximately 4% increase from his fiscal 2008 base salary. The increase in Dr. Knodel’s fiscal 2009 base salary from fiscal 2008 was based on the Compensation Committee’s assessment, based in part on Dr. Hausen’s assessment, of Dr. Knodel’s performance since the prior salary determination and in part on the Compensation Committee’s desire to align compensation with approximately the benchmark group mean.
 
In August 2008, the Compensation Committee re-evaluated Dr. Knodel’s bonus target and concluded that the previously established target of 25% of base salary remained appropriate. The Compensation Committee determined that Dr. Knodel should be rewarded based on 74% achievement of his 25% target bonus, taking into account Cardica’s overall and Dr. Knodel’s individual achievements in fiscal 2008, as discussed above. The Compensation Committee determined that 74% achievement was appropriate in light of the fact that we achieved 90% of our corporate goals and that the Compensation Committee believed, after evaluating all relevant factors, that our failure to achieve the other objectives was not reflective of any failure on the part of Dr. Knodel or our management to take all reasonable steps to achieve those goals, and the Compensation Committee’s assessment of Dr. Knodel’s achievement of his personal goals. Accordingly, Dr. Knodel was awarded a cash bonus award under our 2008 Bonus Plan of $45,103 (74% of 25% of $243,800 base salary for fiscal 2008) as compensation for his performance in fiscal 2008.
 
In fiscal 2008, Dr. Knodel was not granted any equity awards. In fiscal 2009, Dr. Knodel has been granted an option to purchase 25,000 shares of our common stock under the 2005 Plan. The option has an exercise price of $9.20 per share, which was the closing sales price of our common stock as quoted on the Nasdaq Global Select Market on the date of grant. The Compensation Committee determined that the option grant was appropriate to align Dr. Knodel’s annual target awards level with that of the benchmark group mean. The shares subject to the option vest at a rate of 1/48th per month following the date of grant, provided Dr. Knodel continues to provide services to the Company, and has accelerated vesting under certain circumstances as described under “Severance and Change of Control Benefits” above.
 
 
For fiscal 2008, Mr. Newell’s base salary was set at $217,300, or an approximately 6% increase from his prior year’s base salary of $205,000. The increase in Mr. Newell’s fiscal 2008 base salary from fiscal 2007 was based on his overall performance as Chief Financial Officer and Vice President, Finance, our regulatory and clinical progress during fiscal 2007 and his salary relative to peers at other public medical device companies. Mr. Newell’s base salary for fiscal 2009 has been set at $235,300, or an approximately 8% increase from his fiscal 2008 base salary. The increase in Mr. Newell’s fiscal 2009 base salary from fiscal 2008 was based on the Compensation Committee’s assessment, based in part on Dr. Hausen’s assessment, of Mr. Newell’s strong performance since the prior salary determination and in part on the Compensation Committee’s desire to align compensation with approximately the benchmark group mean.
 
In August 2008, the Compensation Committee re-evaluated Mr. Newell’s bonus target and concluded that the previously established target of 25% of base salary remained appropriate. The Compensation Committee determined that Mr. Newell should be rewarded based on 100% achievement of his 25% target bonus, taking into account our overall and Mr. Newell’s individual achievements in fiscal 2008, as discussed above. The Compensation Committee determined that 100% achievement was appropriate in light of the fact that we achieved 90% of our corporate goals and that the Compensation Committee believed, after evaluating all relevant factors, that our failure to achieve the other objectives was not reflective of any failure on the part of Mr. Newell or our management to take all reasonable


32


Table of Contents

steps to achieve those goals, and the Compensation Committee’s assessment of Mr. Newell’s achievement of his personal goals. Accordingly, Mr. Newell was awarded a cash bonus award under our 2008 Bonus Plan of $54,325 (100% of 25% of $217,300 base salary for fiscal 2008) as compensation for his performance in fiscal 2008.
 
In fiscal 2008, Mr. Newell was not granted any equity awards. In fiscal 2009, Mr. Newell has been granted an option to purchase 25,000 shares of our common stock under the 2005 Plan. The option has an exercise price of $9.20 per share, which was the closing sales price of our common stock as quoted on the Nasdaq Global Select Market on the date of grant. The Compensation Committee determined that the option grant was appropriate to align Mr. Newell’s annual target awards level with that of the benchmark group mean. The shares subject to the option vest at a rate of 1/48th per month following the date of grant, provided Mr. Newell continues to provide services to the Company, and has accelerated vesting under certain circumstances as described under “Severance and Change of Control Benefits” above.
 
 
For fiscal 2008, Mr. Ruedy’s base salary was set at $200,000. Because Mr. Ruedy joined our management team April 2007, his salary was not increased for fiscal 2008. Mr. Ruedy’s base salary for fiscal 2009 has been set at $240,000, or an approximately 20% increase from his fiscal 2008 base salary. The increase in Mr. Ruedy’s fiscal 2009 base salary from fiscal 2008 was based on the Compensation Committee’s assessment, based in part on Dr. Hausen’s assessment, of Mr. Ruedy’s strong performance since the prior salary determination and the Compensation Committee’s desire to incentivize and acknowledge Mr. Ruedy’s critical role in our goal to obtain FDA clearance of our PAS-Port system and in our other regulatory endeavors.
 
In August 2008, the Compensation Committee re-evaluated Mr. Ruedy’s bonus target and concluded that the previously established target of 25% of base salary remained appropriate. The Compensation Committee determined that Mr. Ruedy should be rewarded based on 100% achievement of his 25% target bonus, taking into account our overall and Mr. Ruedy’s individual achievements in fiscal 2008, as discussed above. The Compensation Committee determined that 100% achievement was appropriate in light of the fact that we achieved 90% of our corporate goals and that the Compensation Committee believed, after evaluating all relevant factors, that our failure to achieve the other objectives was not reflective of any failure on the part of Mr. Ruedy or our management to take all reasonable steps to achieve those goals, and the Compensation Committee’s assessment of Mr. Ruedy’s achievement of his personal goals. Accordingly, Mr. Ruedy was awarded a cash bonus award under our 2008 Bonus Plan of $50,000 (100% of 25% of $200,000 base salary for fiscal 2008) as compensation for his performance in fiscal 2008.
 
In fiscal 2008, Mr. Ruedy was not granted any equity awards. In fiscal 2009, Mr. Ruedy has been granted an option to purchase 30,000 shares of our common stock under the 2005 Plan. The option has an exercise price of $9.20 per share, which was the closing sales price of our common stock as quoted on the Nasdaq Global Select Market on the date of grant. The Compensation Committee determined that the option grant was appropriate to align Mr. Ruedy’s annual target awards level with that of the benchmark group mean. The shares subject to the option vest at a rate of 1/48th per month following the date of grant, provided Mr. Ruedy continues to provide services to the Company, and has accelerated vesting under certain circumstances as described under “Severance and Change of Control Benefits” above.
 
 
During fiscal 2006, we adopted the fair value provisions of Financial Accounting Standards Board Statement No. 123(R) (revised 2004), “Share-Based Payment,” or SFAS 123R. Under SFAS 123R, we are required to estimate and record an expense for each award of equity compensation (including stock options) over the vesting period of the award. The Compensation Committee has determined to retain for the foreseeable future our stock option program as the sole component of our long-term compensation program, and, therefore, to record this expense on an ongoing basis according to SFAS 123R. The Compensation Committee has considered, and may in the future consider, the grant of restricted stock to Cardica’s named executive officers in lieu of stock option grants in light of the accounting impact of SFAS 123R with respect to stock option grants and other considerations.
 
Section 162(m) of the Internal Revenue Code of 1986 limits our deduction for federal income tax purposes to not more than $1 million of compensation paid to certain executive officers in a calendar year. Compensation above $1 million may be deducted if it is “performance-based compensation.” The Compensation Committee has not yet


33


Table of Contents

established a policy for determining which forms of incentive compensation awarded to Cardica’s named executive officers shall be designed to qualify as “performance-based compensation.” To maintain flexibility in compensating our named executive officers in a manner designed to promote Cardica’s objectives, the Compensation Committee has not adopted a policy that requires all compensation to be deductible. However, the Compensation Committee intends to evaluate the effects of the compensation limits of Section 162(m) on any compensation it proposes to grant, and the Compensation Committee intends to provide future compensation in a manner consistent with our best interests and those of our stockholders.
 
 
The following table shows for the fiscal years ended June 30, 2008 and 2007, compensation awarded to or paid to, or earned by, our Chief Executive Officer, Chief Financial Officer and our three other most highly compensated executive officers at June 30, 2008 (the “Named Executive Officers”).
 
Summary Compensation Table for Fiscal 2008
 
                                                                 
                                  Non-Equity
             
                      Option
    Stock
    Incentive Plan
    All Other
       
          Salary
    Bonus
    Awards
    Awards
    Compensation
    Compensation
    Total
 
Name and Principal Position
  Year     ($)     ($)     ($)(1)     ($)(1)     ($)     ($)     ($)  
 
Dr. Bernard A. Hausen
    2008       312,700                         140,400             312,700  
President and Chief Executive Officer
    2007       295,000             97,988             118,000       1,490 (3)     512,478  
Robert Y. Newell
    2008       217,300                         54,325             271,625  
Vice President, Finance Chief Financial Officer
    2007       205,000             55,709             28,700             289,409  
Douglas T. Ellison
    2008       201,400                   177,066       230,509 (2)           615,335  
Vice President, Sales & Marketing
    2007       196,260       80,000       69,491             79,950             425,701  
Dr. Bryan D. Knodel
    2008       243,800                           45,103       65,100 (4)     354,003  
Vice President, Research and Development
    2007       230,660             28,147             32,200       55,633 (5)     346,640  
Richard M. Ruedy
    2008       200,004                           50,000             250,004  
Vice President, Regulatory, Clinical and Quality Affairs
    2007       41,668             22,984                         64,652  
 
 
(1) As required by applicable regulations, amounts shown in this column reflect our accounting expense for these awards and do not reflect whether the recipient has actually realized a financial benefit from the awards (such as by exercising stock options). This column represents the dollar amount recognized for financial statement reporting purposes with respect to the 2007 and 2008 fiscal years, respectively, for the fair value of stock options and awards granted to the named executive officers. The fair value was estimated using the Black-Scholes option pricing model in accordance with SFAS 123R. Pursuant to SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions. For additional information, including information regarding the valuation assumptions with respect to grants made prior to fiscal 2008, refer to Note 1 of the financial statements in our Form 10-K for the year ended June 30, 2008, as filed with the SEC. See the Grants of Plan-Based Awards table for information regarding awards made in fiscal 2008.
 
(2) Amount received pursuant to bonus plan, under which Mr. Ellison was entitled to receive (i) $46,000 quarterly based on the Company’s gross sales, (ii) 10% of the Company’s gross sales over the gross sales contemplated by the Company’s sales plan and (iii) an additional $1,000 per account on a quarterly basis based on certain objectives.
 
(3) Consists of the value of insurance premiums paid by us on Dr. Hausen’s behalf
 
(4) Consists of $63,000 of reimbursed travel expenses and $1,200 of reimbursed medical expenses for fiscal 2008.
 
(5) Consists of the amount of reimbursed travel expenses for fiscal 2007.


34


Table of Contents

 
 
The following table shows for the fiscal year ended June 30, 2008, certain information regarding grants of plan-based awards to our Named Executive Officers:
 
 
                                     
        Estimated Future
                   
        Payouts Under
    All Other
             
        Non-Equity
    Stock
             
        Incentive Plan
    Awards:
    Exercise or Base
    Grant Date Fair
 
        Awards
    Number of
    Price of Stock
    Value of Stock and
 
        Target
    Securities
    Awards
    Option Awards
 
Name
  Grant Date   ($)     (#)(1)     ($/Sh)(2)     ($)(3)  
 
Dr. Bernard A. Hausen
  2/6/08     156,350                          
Robert Y. Newell
  2/6/08     54,325                          
Douglas T. Ellison
  10/10/07           40,000 (4)   $ 13.70       177,066  
    6/27/07     184,000                          
Dr. Bryan D. Knodel
  2/6/08     60,950                          
Richard M. Ruedy
  2/6/08     50,000                          
 
 
(1) This column shows the number of shares of common stock granted to the named executives in fiscal 2008.
 
(2) The base price for the stock options granted was the closing fair market value of our common stock on the date of grant, which was the date the Board approved the options.
 
(3) The amount shown in this column is the full grant date fair value of the options granted computed under SFAS 123R. The full grant date fair value is the amount we would expense in its financial statements over the option’s vesting period.
 
(4) One-fourth (1/4th) of the shares of common stock subject to the stock award vest on October 10th of each of 2008, 2009, 2010 and 2011, respectively, provided in each case that Mr. Ellison is then providing continuous service to Cardica (as defined in the 2005 Equity Incentive Plan). The stock award is subject to accelerated vesting such that 50% of the then-unvested shares subject to the stock award shall become immediately vested upon a change in control, provided that Mr. Ellison is still providing service to Cardica at that time, and 100% of the shares subject to the stock award will immediately vest if Mr. Ellison is terminated without cause or resigns for good reason one month prior to or 13 months following the closing of a change in control.
 
As of September 1, 2008, awards covering an aggregate of 1,146,208 shares of common stock were outstanding under the 2005 Plan, and awards covering an aggregate of 582,596 shares of common stock were outstanding under the 1997 Equity Incentive Plan (the “1997 Plan”). The 1997 Plan has terminated, but there were options outstanding under the 1997 Plan prior to its termination that continue to be governed by the terms of the 1997 Plan. An aggregate of 19,098 shares of common stock have been issued pursuant to the exercise of awards issued under the 2005 Plan.
 
As of September 1, 2008, a total of 801,991 shares of common stock were included in the share reserve under the 2005 Plan, and 64,208 shares of common stock remained available for future grant under the 2005 Plan. In addition, if any stock award under the 1997 Plan expires or otherwise terminates, in whole or in part, without having been exercised in full, or if any shares of common stock issued pursuant to a stock award under the 1997 Plan are forfeited back to us because of the failure to meet a contingency or condition required to vest such shares in the holder of the stock award, the share reserve of the 2005 Plan automatically increases by the number of shares of common stock not acquired or forfeited. The number of shares available for future grant under the 2005 Plan will also increase if shares covered by outstanding awards revert to the 2005 Plan as discussed more fully above with respect to Proposal 2 under the heading “General.”
 
In the event of certain significant corporate transactions, such as a sale of substantially all of our assets or a merger or consolidation where we are not the surviving entity, all outstanding stock awards under the Incentive Plans may be assumed, continued or substituted with similar stock awards. Additionally, certain stock awards may


35


Table of Contents

be subject to additional acceleration of vesting and exercisability upon or after a change-in-control as provided in the stock award agreement for such stock award.
 
 
The following table shows for the fiscal year ended June 30, 2008, certain information regarding outstanding equity awards at fiscal year end for our Named Executive Officers.
 
Outstanding Equity Awards At June 30, 2008
 
                                                 
    Option Awards     Stock Awards  
    Number of
    Number of
                      Market
 
    Securities
    Securities
                Number of
    Value of
 
    Underlying
    Underlying
                Shares or
    Shares or
 
    Unexercised
    Unexercised
    Option
          Units of
    Units of
 
    Options
    Options
    Exercise
    Option
    Stock That
    Stock That
 
    (#)
    (#)
    Price
    Expiration
    Have Not
    Have Not
 
Name
  Exercisable     Unexercisable(1)     ($)     Date     Vested ($)     Vested ($)  
 
Dr. Bernard A. Hausen
    50,000       0       2.25       3/4/13              
      33,333       0       2.25       5/27/13              
      35,087       0       2.85       3/23/14              
      14,912       0       2.85       3/23/14              
      20,000       0       2.85       7/18/15              
      20,000       0       2.85       7/18/15              
      19,687       15,313       8.00       3/28/16              
      14,895       50,105       6.03       6/26/17              
Robert Y. Newell
    26,666       0       2.25       5/27/13              
      6,000       0       2.85       3/23/14              
      20,000       0       2.85       7/18/15              
      11,250       8,750       8.00       3/28/16              
      5,729       19,271       6.03       6/26/17              
Douglas T. Ellison
    31,087       0       2.85       2/1/15       40,000       177,066  
      64,913       0       2.85       2/1/15              
      14,062       10,938       8.00       3/28/16              
      5,729       19,271       6.03       6/26/17              
Dr. Bryan D. Knodel
    862       0       2.85       1/28/14              
      1,784       0       2.85       3/23/14              
      1,688       0       2.85       5/18/14              
      6,666       0       2.85       5/18/14              
      6,666       0       2.85       5/18/14              
      1,660       0       2.85       7/13/14              
      1,723       0       2.85       9/20/14              
      2,401       0       2.85       11/16/14              
      2,195       0       2.85       2/01/15              
      1,450       0       2.85       3/23/15              
      3,561       0       2.85       7/18/15              
      31,579       0       2.85       7/18/15              
      35,087       0       2.85       7/18/15              
      5,625       4,375       8.00       3/28/16              
      5,729       19,271       6.03       6/26/17              
Richard M. Ruedy
    17,500       42,500 (2)     6.00       4/25/07              
      2,520       8,480       6.03       6/27/07              
 
 
(1) Except where noted, unvested options vest in installments of 1/48th of the total grant per month, so long as the holder is providing continuous service to us.
 
(2) 1/4th of the shares vested on April 25, 2008 and 1/48th of the grant vest monthly thereafter so long as the holder is providing continuous service to us. This option is subject to accelerated vesting as described under “Potential Payments Upon Termination or Change-in-Control” below.


36


Table of Contents

 
No options were exercised by the Named Executive Officers in fiscal 2008.
 
 
The amount of compensation and benefits payable to each named executive officer in various change-in-control and/or termination situations has been estimated in the tables below. The tables below do not include amounts in which the named executive officer had already vested as of June 30, 2008. Such vested amounts would include vested stock options and accrued wages and vacation. The tables below also do not include the impact of equity awards granted to the named executive officers after June 30, 2008.
 
In addition to amounts below, our Board has the discretion to provide that a stock award under the 2005 Plan will immediately vest as to all or any portion of the shares subject to the stock award (i) immediately upon the occurrence of specified change-in-control transactions, whether or not such stock award is assumed, continued or substituted by a surviving or acquiring entity in the transaction, or (ii) in the event a participant’s service with us or a successor entity is terminated actually or constructively within a designated period following the occurrence of specified change-in-control transactions. Stock awards held by participants under 2005 Plan will not vest on such an accelerated basis unless specifically provided by the participant’s applicable award agreement. The currently provided-for acceleration for our named executive officers is explained below.
 
The actual amount of compensation and benefits payable in any termination event can only be determined at the time of the termination of the named executive officer’s employment with Cardica.
 
 
Dr. Hausen has entered into a benefit agreement that provides that, if at any time Dr. Hausen’s employment is terminated by us without cause or if Dr. Hausen resigns for good reason, we would be obligated to pay Dr. Hausen severance equal to 12 months of salary. Subject only to our obligation to pay this severance amount under the circumstances described, Dr. Hausen’s employment by us is “at will,” which means that either he or we may terminate his employment with us at any time and for any reason or for no reason.
 
The following table describes the potential payments and benefits upon employment termination and/or change in control for Dr. Hausen as if such event occurred as of June 30, 2008, the last business day of Cardica’s last fiscal year.
 
                         
    Termination
          Termination Without Cause
 
    Without Cause or
          or for Good Reason Within
 
    for Good Reason
          One Month Prior to or 13
 
    (No Change
    Change in
    Months Following
 
Compensation and Benefits
  in Control) ($)     Control ($)     a Change in Control ($)  
 
Base Salary Payment (Lump Sum)
    350,000       0       350,000  
Stock Option Vesting Acceleration(1)
    0       99,465       198,930  
                         
Total
    350,000       99,465       548,930  
                         
 
 
The following table describes the potential payments and benefits to Mr. Newell upon a change in control of Cardica and/or upon the termination of Mr. Newell’s employment without cause or for good reason within one month prior to or 13 months following a change in control as if such event occurred as of June 30, 2008, the last business day of Cardica’s last fiscal year.
 
                 
          Termination Without Cause or
 
          for Good Reason Within One Month
 
    Change in
    Prior to or 13 Months Following a
 
Compensation and Benefits
  Control ($)     Change in Control ($)  
 
Stock Option Vesting Acceleration(1)
    40,621       81,243  


37


Table of Contents

 
The following table describes the potential payments and benefits to Mr. Ellison upon a change in control of Cardica and/or upon the termination of Mr. Ellison’s employment without cause or for good reason within one month prior to or 13 months following a change in control as if such event occurred as of June 30, 2008, the last business day of Cardica’s last fiscal year.
 
                 
          Termination Without Cause or
 
          for Good Reason Within One Month
 
    Change in
    Prior to or 13 Months Following a
 
Compensation and Benefits
  Control ($)     Change in Control ($)  
 
Stock Option Vesting Acceleration(1)
    60,995       121,991  
Stock Award Vesting Acceleration(1)
    169,200       338,400  
                 
Total
    230,195       460,391  
                 
 
 
The following table describes the potential payments and benefits to Mr. Knodel upon a change in control of Cardica and/or upon the termination of Mr. Knodel’s employment without cause or for good reason within one month prior to or 13 months following a change in control as if such event occurred as of June 30, 2008, the last business day of Cardica’s last fiscal year.
 
                 
          Termination Without Cause or
 
          for Good Reason Within One Month
 
    Change in
    Prior to or 13 Months Following a
 
Compensation and Benefits
  Control ($)     Change in Control ($)  
 
Stock Option Vesting Acceleration(1)
    75,068       150,135  
 
 
The following table describes the potential payments and benefits to Mr. Ruedy upon a change in control of Cardica and/or upon the termination of Mr. Ruedy’s employment without cause or for good reason within one month prior to or 13 months following a change in control as if such event occurred as of June 30, 2008, the last business day of Cardica’s last fiscal year.
 
                 
          Termination Without Cause or
 
          for Good Reason Within One Month
 
    Change in
    Prior to or 13 Months Following a
 
Compensation and Benefits
  Control ($)     Change in Control ($)  
 
Stock Option Vesting Acceleration(1)
    62,578       125,156  
 
 
(1) Equity awards held by Dr. Hausen and by Messrs. Newell, Ellison, Knodel and Ruedy are subject to accelerated vesting such that 50% of the then-unvested shares subject to the awards shall become immediately vested upon a change-in-control, and 100% of the then-unvested shares subject to the wards held by each shall become immediately vested if, within one month prior to or 13 months following a change-in-control, such officer is terminated without cause or resigns for good reason. The value of vesting acceleration set forth in the tables above is based on the closing price of Cardica common stock on June 30, 2008 ($8.46) with respect to in-the-money unvested option shares minus the exercise price of the unvested option shares.


38


Table of Contents

 
 
The following table shows for the fiscal year ended June 30, 2008 certain information with respect to the compensation of all of our non-employee directors:
 
Director Compensation for Fiscal 2008
 
                         
    Fees Earned or
    Option
       
    Paid in Cash
    Awards
    Total
 
Name
  ($)(1)     ($)(3)     ($)  
 
J. Michael Egan
    18,500 (2)     19,350       37,850  
Kevin T. Larkin
    30,000       19,350       49,350  
Richard P. Powers
    27,500 (2)     19,350       46,850  
Jeffrey L. Purvin
    19,500 (2)     19,350       38,850  
Robert C. Robbins, M.D. 
    18,000 (2)     19,350       37,350  
John Simon, Ph.D. 
    20,000 (2)     19,350       39,350  
Stephen A. Yencho, Ph.D. 
    20,500 (2)     19,350       39,850  
William H. Younger, Jr. 
    20,500 (2)     19,350       39,850  
 
 
(1) Amounts shown in this column represent the annual fees paid to each director in fiscal year 2008 under our non-employee director compensation plan as discussed below.
 
(2) Amount includes $2,000 earned during fiscal year 2007 and paid during fiscal year 2008.
 
(3) The amounts in this column represent the amount recognized for the fiscal year ended June 30, 2008, for financial statement reporting purposes in accordance with FAS 123R and therefore may include amounts from awards granted prior to fiscal 2008. Pursuant to SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions. Assumptions used in the calculation of these amounts are included in footnote 1 to our audited financial statements for the year ended June 30, 2008 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on September   , 2008. The aggregate grant date fair value computed in accordance with FAS 123R for the option awards grants in fiscal 2008 was $19,350 for Mr. Egan, $19,350 for Mr. Larkin, $19,350 for Mr. Powers, $19,350 for Mr. Purvin, $19,350 for Dr. Robbins, $19,350 for Mr. Simon, $19,350 for Mr. Yencho and $19,350 for Mr. Younger.
 
Effective January 11, 2007, our board adopted the non-employee director compensation plan, which provides for the following compensation to non-employee directors:
 
                         
          Per Board
    Per Board
 
    Annual
    Meeting in
    Meeting by
 
Position
  Retainer     Person     Telephone  
 
Board Chairman
  $ 30,000     $ 2,000     $ 500  
Audit Committee Chair
  $ 17,500     $ 2,000     $ 500  
Board Member
  $ 10,000     $ 2,000     $ 500  
 
Each non-employee director is entitled to one annual retainer fee. On November 14, 2007, each non-employee director was granted a fully-vested option to purchase 2,500 shares of our common stock, with each such option subject to a four year term. Each year, immediately following our annual stockholders meeting, each non-employee director will be granted a fully-vested option to purchase 2,500 shares of our common stock, with each such option subject to a four year term.


39


Table of Contents

On August 13, 2008, our Board, upon recommendation of the Compensation Committee, approved changes in our non-employee director compensation. The new cash compensation is as follows:
 
                                 
                      Committee
 
    Annual
    Board Meeting Attended     Meeting
 
Position
  Retainer     In Person     By Telephone     Attended  
 
Board Chairman
  $ 30,000     $ 2,000     $ 500     $ 500  
Audit Committee Chairman
  $ 30,000     $ 2,000     $ 500     $ 500  
Compensation Committee Chairman
  $ 27,500     $ 2,000     $ 500     $ 500  
Nominating and Corporate Governance Committee Chairman
  $ 25,000     $ 2,000     $ 500     $ 500  
Board Member (other than Board or Committee Chairs)
  $ 20,000     $ 2,000     $ 500     $ 500  
 
Each non-employee director will only be entitled to one annual retainer fee. Additionally, the Board, upon recommendation of the Compensation Committee, increased to 5,000 shares the annual option grants to non-employee directors, which will be granted each year immediately following our Annual Meeting of Stockholders. Each such option will vest monthly over the ensuing year. The Board also approved granting to any new non-employee director, automatically upon his or her becoming a director, an option to purchase 15,000 shares of the Company’s common stock, vesting monthly over three years.
 
Transactions With Related Persons
 
 
Our Code of Business Conduct and Ethics provides that any transaction that may involve a conflict of interest and involves any executive officer or director of ours, including any of their immediate family members, and any entity owned or controlled by such persons must be authorized by our Audit Committee or other independent committee of the Board.
 
 
We describe below transactions and series of transactions that have occurred since July 1, 2007 to which we were a party in which:
 
  •  the amounts involved exceeded or will exceed $120,000; and a
 
  •  director, executive officer, holder of more than 5% of our common stock or any member of their immediate family had or will have a direct or indirect material interest.
 
Compensation arrangements with our Named Executive Officers are described under the caption “Potential Payments Upon Termination or Change-in-Control.”
 
 
Our amended and restated certificate of incorporation provides that the liability of our directors for monetary damages shall be eliminated to the fullest extent permissible under the General Corporation Law of the State of Delaware. This provision does not eliminate a director’s duty of care and, in appropriate circumstances, equitable remedies such as an injunction or other forms of non-monetary relief would remain available. Each director will continue to be subject to liability for any breach of the director’s duty of loyalty to us or our stockholders and for acts or omissions not in good faith or involving intentional misconduct or knowing violations of law, for unlawful payment of dividends or stock repurchases or for any transaction in which the director derived an improper personal benefit. This provision also does not affect a director’s responsibilities under any other laws, such as the federal securities laws or other state or federal laws.
 
Our amended and restated bylaws provide that we will indemnify our directors and executive officers, and may indemnify our other officers, employees and agents, to the fullest extent permitted by the General Corporation Law


40


Table of Contents

of the State of Delaware. Under our amended and restated bylaws, we are also empowered to enter into indemnification agreements with our directors, officers and other agents and to purchase insurance on behalf of any person whom we are required or permitted to indemnify. We have procured and intend to maintain a directors’ and officers’ liability insurance policy that insures such persons against the costs of defense, settlement or payment of a judgment under certain circumstances.
 
We have entered into an indemnification agreement with Stephen Yencho. Under this agreement, we are required to indemnify Dr. Yencho against all expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any actual or threatened proceeding, if he may be made a party to such proceeding because he is or was one of our directors or officers. We are obligated to pay these amounts only if Dr. Yencho acted in good faith and in a manner that he reasonably believed to be in, or not opposed to, our best interests. The indemnification agreement also sets forth procedures that will apply in the event of a claim for indemnification. We are also obligated to advance expenses, subject to an undertaking to repay amounts advanced if Dr. Yencho is ultimately determined not to be entitled to indemnification.
 
There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer.
 
 
Certain stock options held by Dr. Hausen, Mr. Newell, Mr. Ellison, Mr. Knodel and Mr. Reudy are subject to accelerated vesting upon a change-in-control, as described under “Potential Payments Upon Termination or Change-in-Control.
 
 
Dr. Hausen is entitled to severance pay as described under “Potential Payments Upon Termination or Change-in-Control.”
 
 
In June 2007, we completed a private placement to a group of accredited investors in reliance on Rule 506 promulgated under the Securities Act of 1933, as amended, without general solicitation or advertising. Allen & Company LLC received a fee of $360,000 for advisory services in connection with this transaction, which was paid in fiscal year 2008. John Simon, a member of our Board, is a managing director of Allen & Company LLC.
 
 
In November 2007, we sold 1,500,000 shares of our common stock in an underwritten public offering pursuant to our shelf registration statement on Form S-3, declared effective on October 19, 2007. Allen & Company LLC acted as co-managing underwriter in connection with this offering and received underwriting fees.
 
 
The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy statements and annual reports with respect to two or more stockholders sharing the same address by delivering a single proxy statement addressed to those stockholders. This process, which is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for companies.
 
This year, a number of brokers with account holders who are Cardica, Inc. stockholders will be “householding” our proxy materials. A single proxy statement will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be “householding” communications to your address, “householding” will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in


41


Table of Contents

“householding” and would prefer to receive a separate proxy statement and annual report, please notify your broker. In addition, you may also direct your written request to Cardica, Inc., 900 Saginaw Drive, Redwood City, California 94063, Attn: Robert Y. Newell, Secretary or contact Robert Y. Newell at (650) 364-9975. Stockholders who currently receive multiple copies of the proxy statement at their address and would like to request “householding” of their communications should contact their broker.
 
 
The Board knows of no other matters that will be presented for consideration at the annual meeting. If any other matters are properly brought before the annual meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment.
 
By Order of the Board of Directors
 
-s- Robert Y. Newell
Robert Y. Newell
Secretary
 
October 9, 2008
 
A copy of our Annual Report to the SEC on Form 10-K for the fiscal year ended June 30, 2008 is available without charge upon written request to: Corporate Secretary, Robert Y. Newell, Cardica, Inc., 900 Saginaw Drive, Redwood City, California 94063.
 
The information required by Items 401(b) and (c) of Regulation S-K regarding our executive officers and significant employees is set forth under the caption “Management” in Item 1 of our Annual Report to the SEC on Form 10-K for the fiscal year ended June 30, 2008 and incorporated herein by reference.


42


Table of Contents

Annex A
 
2005 Equity Incentive Plan, As Amended
 
Cardica, Inc.
 
2005 Equity Incentive Plan
 
Adopted by the Board of Directors: October 13, 2005
Approved by the Stockholders: December 27, 2005
As Amended by the Board of Directors: September 29, 2006
Approved by the Stockholders: November 8, 2006
As Amended by the Board of Directors: October 10, 2007
Approved by the Stockholders: November 14, 2007
As Amended by the Board of Directors: August 13, 2008
Approved by the Stockholders:                      
Termination Date: October 12, 2015
 
1.   General.
 
(a) Eligible Stock Award Recipients.  The persons eligible to receive Stock Awards are Employees, Directors and Consultants.
 
(b) Available Stock Awards.  The Plan provides for the grant of the following Stock Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Purchase Awards, (iv) Stock Bonus Awards, (v) Stock Appreciation Rights, (vi) Stock Unit Awards, and (vii) Other Stock Awards.
 
(c) Purpose.  The Company, by means of the Plan, seeks to secure and retain the services of the group of persons eligible to receive Stock Awards as set forth in Section 1(a), to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such eligible recipients may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Stock Awards.
 
2.   Definitions.
 
As used in the Plan, the following definitions shall apply to the capitalized terms indicated below:
 
(a) “Affiliate” means (i) any corporation (other than the Company) in an unbroken chain of corporations ending with the Company, provided each corporation in the unbroken chain (other than the Company) owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain, and (ii) any corporation (other than the Company) in an unbroken chain of corporations beginning with the Company, provided each corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. The Board shall have the authority to determine (i) the time or times at which the ownership tests are applied, and (ii) whether “Affiliate” includes entities other than corporations within the foregoing definition.
 
(b) “Board” means the Board of Directors of the Company.
 
(c) “Capitalization Adjustment” has the meaning ascribed to that term in Section 10(a).
 
(d) “Cause” means, with respect to a Participant, the occurrence of any of the following: (i) such Participant’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) such Participant’s attempted commission of, or participation in, a fraud or act of dishonesty against the Company; (iii) such Participant’s intentional, material violation of any material contract or agreement between the Participant and the Company or any statutory duty owed to the Company; (iv) such Participant’s unauthorized use or disclosure of the Company’s confidential information or


A-1


Table of Contents

trade secrets; or (v) such Participant’s gross misconduct. The determination that a termination is for Cause shall be made by the Company in its sole discretion. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Stock Awards held by such Participant shall have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose.
 
(e) “Change in Control” means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:
 
(i) any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person from the Company in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities or (B) solely because the level of Ownership held by any Exchange Act Person (the “Subject Person”) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur;
 
(ii) there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A) outstanding voting securities representing more than fifty percent (50%) of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than fifty percent (50%) of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction;
 
(iii) the stockholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company shall otherwise occur;
 
(iv) there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than fifty percent (50%) of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; or
 
(v) individuals who, on the date this Plan is adopted by the Board, are members of the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board.
 
The term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.


A-2


Table of Contents

Notwithstanding the foregoing or any other provision of this Plan, the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Stock Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply.
 
(f) “Code” means the Internal Revenue Code of 1986, as amended.
 
(g) “Committee” means a committee of one (1) or more members of the Board to whom authority has been delegated by the Board in accordance with Section 3(c).
 
(h) “Common Stock” means the common stock of the Company.
 
(i) “Company” means Cardica, Inc., a Delaware corporation.
 
(j) “Consultant” means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the Board of Directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, shall not cause a Director to be considered a “Consultant” for purposes of the Plan.
 
(k) “Continuous Service” means that the Participant’s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant’s service with the Company or an Affiliate, shall not terminate a Participant’s Continuous Service; provided, however, if the corporation for which a Participant is rendering service ceases to qualify as an Affiliate, as determined by the Board in its sole discretion, such Participant’s Continuous Service shall be considered to have terminated on the date such corporation ceases to qualify as an Affiliate. For example, a change in status from an employee of the Company to a consultant of an Affiliate or to a Director shall not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party’s sole discretion, may determine whether Continuous Service shall be considered interrupted in the case of any leave of absence approved by that party, including sick leave, military leave or any other personal leave. Notwithstanding the foregoing, a leave of absence shall be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company’s leave of absence policy or in the written terms of the Participant’s leave of absence.
 
(l) “Corporate Transaction” means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:
 
(i) a sale or other disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Company and its Subsidiaries;
 
(ii) a sale or other disposition of at least ninety percent (90%) of the outstanding securities of the Company;
 
(iii) the consummation of a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or
 
(iv) the consummation of a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.
 
(m) “Covered Employee” means the chief executive officer and the four (4) other highest compensated officers of the Company for whom total compensation is required to be reported to stockholders under the Exchange Act, as determined for purposes of Section 162(m) of the Code.


A-3


Table of Contents

(n) “Director” means a member of the Board.
 
(o) “Disability” means the permanent and total disability of a person within the meaning of Section 22(e)(3) of the Code.
 
(p) “Employee” means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, shall not cause a Director to be considered an “Employee” for purposes of the Plan.
 
(q) “Entity” means a corporation, partnership or other entity.
 
(r) “Exchange Act” means the Securities Exchange Act of 1934, as amended.
 
(s) “Exchange Act Person” means any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that “Exchange Act Person” shall not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the effective date of the Plan as set forth in Section 13, is the Owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power of the Company’s then outstanding securities.
 
(t) “Fair Market Value” means, as of any date, the value of the Common Stock determined as follows:
 
(i) If the Common Stock is listed on any established stock exchange or traded on the Nasdaq Global Market (formerly the Nasdaq National Market) or the Nasdaq Capital Market (formerly the Nasdaq SmallCap Market), the Fair Market Value of a share of Common Stock shall be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date in question, as reported in The Wall Street Journal or such other source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price (or closing bid if no sales were reported) for the Common Stock on the date in question, then the Fair Market Value shall be the closing sales price (or closing bid if no sales were reported) on the last preceding date for which such quotation exists.
 
(ii) In the absence of such markets for the Common Stock, the Fair Market Value shall be determined by the Board in good faith.
 
(u) “Incentive Stock Option” means an Option intended to qualify as an incentive stock option within the meaning of Section 422 of the Code and the regulations promulgated thereunder.
 
(v) “IPO Date” means the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering.
 
(w) “Non-Employee Director” means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (“Regulation S-K”)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item 404(b) of Regulation S-K; or (ii) is otherwise considered a “non-employee director” for purposes of Rule 16b-3.
 
(x) “Nonstatutory Stock Option” means an Option not intended to qualify as an Incentive Stock Option.


A-4


Table of Contents

(y) “Officer” means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules and regulations promulgated thereunder.
 
(z) “Option” means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.
 
(aa) “Option Agreement” means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant. Each Option Agreement shall be subject to the terms and conditions of the Plan.
 
(bb) “Optionholder” means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.
 
(cc) “Other Stock Award” means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 7(f).
 
(dd) “Other Stock Award Agreement” means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement shall be subject to the terms and conditions of the Plan.
 
(ee) “Outside Director” means a Director who either (i) is not a current employee of the Company or an “affiliated corporation” (within the meaning of Treasury Regulations promulgated under Section 162(m) of the Code), is not a former employee of the Company or an “affiliated corporation” who receives compensation for prior services (other than benefits under a tax-qualified retirement plan) during the taxable year, has not been an officer of the Company or an “affiliated corporation,” and does not receive remuneration from the Company or an “affiliated corporation,” either directly or indirectly, in any capacity other than as a Director, or (ii) is otherwise considered an “outside director” for purposes of Section 162(m) of the Code.
 
(ff) “Own,” “Owned,” “Owner,” “Ownership” A person or Entity shall be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership” of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.
 
(gg) “Participant” means a person to whom a Stock Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.
 
(hh) “Performance Criteria” means the one or more criteria that the Board shall select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that shall be used to establish such Performance Goals may be based on any one of, or combination of, the following: (i) earnings per share; (ii) earnings before interest, taxes and depreciation; (iii) earnings before interest, taxes, depreciation and amortization (EBITDA); (iv) net earnings; (v) return on equity; (vi) return on assets, investment, or capital employed; (vii) operating margin; (viii) gross margin; (ix) operating income; (x) net income (before or after taxes); (xi) net operating income; (xii) net operating income after tax; (xiii) pre- and after-tax income; (xiv) pre-tax profit; (xv) operating cash flow; (xvi) sales or revenue targets; (xvii) increases in revenue or product revenue; (xviii) expenses and cost reduction goals; (xix) improvement in or attainment of expense levels; (xx) improvement in or attainment of working capital levels; (xxi) economic value added; (xxii) market share; (xxiii) cash flow; (xxiv) cash flow per share; (xxv) share price performance; (xxvi) debt reduction; (xxvii) implementation or completion of projects or processes; (xxviii) customer satisfaction; (xxix) total stockholder return; (xxx) stockholders’ equity; and (xxxi) other measures of performance selected by the Board. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the Stock Award Agreement. The Board shall, in its sole discretion, define the manner of calculating the Performance Criteria it selects to use for such Performance Period.
 
(ii) “Performance Goals” means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or a relevant index. The Board is authorized to make adjustments in the method of calculating the attainment of


A-5


Table of Contents

Performance Goals for a Performance Period as follows: (i) to exclude restructuring and/or other nonrecurring charges; (ii) to exclude exchange rate effects, as applicable, for non-U.S. dollar denominated net sales and operating earnings; (iii) to exclude the effects of changes to generally accepted accounting standards required by the Financial Accounting Standards Board; (iv) to exclude the effects of any statutory adjustments to corporate tax rates; and (v) to exclude the effects of any “extraordinary items” as determined under generally accepted accounting principles. The Board also retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of Performance Goals.
 
(jj) “Performance Period” means the one or more periods of time, which may be of varying and overlapping durations, as the Committee may select, over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant’s right to and the payment of a Stock Award.
 
(kk) “Performance Stock Award” means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 7(e).
 
(ll) “Plan” means this Cardica, Inc. 2005 Equity Incentive Plan.
 
(mm) “Prior Plan” means the Company’s 1997 Equity Incentive Plan in effect immediately prior to the effective date of the Plan as set forth in Section 13.
 
(nn) “Rule 16b-3” means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.
 
(oo) “Securities Act” means the Securities Act of 1933, as amended.
 
(pp) “Stock Appreciation Right” means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 7(d).
 
(qq) “Stock Appreciation Right Agreement” means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement shall be subject to the terms and conditions of the Plan.
 
(rr) “Stock Award” means any right granted under the Plan, including an Option, a Stock Purchase Award, Stock Bonus Award, a Stock Appreciation Right, a Stock Unit Award, Performance Stock Award, or any Other Stock Award.
 
(ss) “Stock Award Agreement” means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant. Each Stock Award Agreement shall be subject to the terms and conditions of the Plan.
 
(tt) “Stock Bonus Award” means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 7(b).
 
(uu) “Stock Bonus Award Agreement” means a written agreement between the Company and a holder of a Stock Bonus Award evidencing the terms and conditions of a Stock Bonus Award grant. Each Stock Bonus Award Agreement shall be subject to the terms and conditions of the Plan.
 
(vv) “Stock Purchase Award” means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 7(a).
 
(ww) “Stock Purchase Award Agreement” means a written agreement between the Company and a holder of a Stock Purchase Award evidencing the terms and conditions of a Stock Purchase Award grant. Each Stock Purchase Award Agreement shall be subject to the terms and conditions of the Plan.
 
(xx) “Stock Unit Award” means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section 7(c).
 
(yy) “Stock Unit Award Agreement” means a written agreement between the Company and a holder of a Stock Unit Award evidencing the terms and conditions of a Stock Unit Award grant. Each Stock Unit Award Agreement shall be subject to the terms and conditions of the Plan.


A-6


Table of Contents

(zz) “Subsidiary” means, with respect to the Company, (i) any corporation of which more than fifty percent (50%) of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation shall have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than fifty percent (50%).
 
(aaa) “Ten Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or any Affiliate.
 
3.   Administration.
 
(a) Administration by Board.  The Board shall administer the Plan unless and until the Board delegates administration of the Plan to a Committee, as provided in Section 3(c).
 
(b) Powers of Board.  The Board shall have the power, subject to, and within the limitations of, the express provisions of the Plan:
 
(i) To construe and interpret the Plan and Stock Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner and to the extent it shall deem necessary or expedient to make the Plan fully effective.
 
(ii) To determine from time to time (1) which of the persons eligible under the Plan shall be granted Stock Awards; (2) when and how each Stock Award shall be granted; (3) what type or combination of types of Stock Award shall be granted; (4) the provisions of each Stock Award granted (which need not be identical), including the time or times when a person shall be permitted to receive cash or Common Stock pursuant to a Stock Award; and (5) the number of shares of Common Stock with respect to which a Stock Award shall be granted to each such person.
 
(iii) To accelerate the time at which a Stock Award may first be exercised or the time during which a Stock Award or any part thereof will vest in accordance with the Plan, notwithstanding the provisions in the Stock Award stating the time at which it may first be exercised or the time during which it will vest.
 
(iv) To amend the Plan or a Stock Award as provided in Section 11.
 
(v) To terminate or suspend the Plan as provided in Section 12.
 
(vi) Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company which are not in conflict with the provisions of the Plan.
 
(vii) To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees who are foreign nationals or employed outside the United States.
 
(c) Delegation to Committee.
 
(i) General.  The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration is delegated to a Committee, the Committee shall have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board shall thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.


A-7


Table of Contents

(ii) Section 162(m) and Rule 16b-3 Compliance.  In the sole discretion of the Board, the Committee may consist solely of two (2) or more Outside Directors, in accordance with Section 162(m) of the Code, and/or solely of two or more Non-Employee Directors, in accordance with Rule 16b-3. In addition, the Board or the Committee, in its sole discretion, may (1) delegate to a committee of one or more members of the Board who need not be Outside Directors the authority to grant Stock Awards to eligible persons who are either (a) not then Covered Employees and are not expected to be Covered Employees at the time of recognition of income resulting from such Stock Award, or (b) not persons with respect to whom the Company wishes to comply with Section 162(m) of the Code, and/or (2) delegate to a committee of one or more members of the Board who need not be Non-Employee Directors the authority to grant Stock Awards to eligible persons who are not then subject to Section 16 of the Exchange Act.
 
(d) Delegation to an Officer.  The Board may delegate to one or more Officers of the Company the authority to do one or both of the following (i) designate Officers and Employees of the Company or any of its Subsidiaries to be recipients of Stock Awards and the terms thereof, and (ii) determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Officers and Employees; provided, however, that the Board resolutions regarding such delegation shall specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself. Notwithstanding anything to the contrary in this Section 3(d), the Board may not delegate to an Officer authority to determine the Fair Market Value of the Common Stock pursuant to Section 2(t)(ii) above.
 
(e) Effect of Board’s Decision.  All determinations, interpretations and constructions made by the Board in good faith shall not be subject to review by any person and shall be final, binding and conclusive on all persons.
 
(f) Cancellation and Re-Grant of Stock Awards.  Neither the Board nor any Committee shall have the authority to: (i) reprice any outstanding Stock Awards under the Plan, or (ii) cancel and re-grant any outstanding Stock Awards under the Plan, unless the stockholders of the Company have approved such an action within a twelve (12) month period preceding or following such an event.
 
4.   Shares Subject to the Plan.
 
(a) Share Reserve.  Subject to the provisions of Section 10(a) relating to Capitalization Adjustments, the number of shares of Common Stock that may be issued pursuant to Stock Awards shall not exceed, in the aggregate, 1,658,377 shares of Common Stock. Such share reserve consists of the number of shares remaining available for future issuance under the Prior Plan as of immediately prior to the termination of the Prior Plan, plus an additional 1,650,000 shares of Common Stock. In addition, the share reserve shall be increased from time to time by the number of shares of Common Stock that (i) are issuable pursuant to stock awards outstanding under the Company’s Prior Plan as of the effective date of the Plan (as set forth in Section 13), and (ii) but for the termination of the Prior Plan as of the effective date of the Plan, would otherwise have reverted to the share reserve of the Prior Plan.
 
(b) Reversion of Shares to the Share Reserve.  If any Stock Award shall for any reason expire or otherwise terminate, in whole or in part, without having been exercised in full, if any shares of Common Stock issued to a Participant pursuant to a Stock Award are forfeited to or repurchased by the Company, including, but not limited to, any repurchase or forfeiture caused by the failure to meet a contingency or condition required for the vesting of such shares, or if any shares of Common Stock are cancelled in accordance with the cancellation and regrant provisions of Section 3(f), then the shares of Common Stock not issued under such Stock Award, or forfeited to or repurchased by the Company, shall revert to and again become available for issuance under the Plan. If any shares subject to a Stock Award are not delivered to a Participant because such shares are withheld for the payment of taxes or the Stock Award is exercised through a reduction of shares subject to the Stock Award (i.e., “net exercised”), the number of shares that are not delivered to the Participant shall remain available for issuance under the Plan. If the exercise price of any Stock Award is satisfied by tendering shares of Common Stock held by the Participant (either by actual delivery or attestation), then the number of shares so tendered shall remain available for issuance under the Plan. Notwithstanding anything to the contrary in this Section 4(b), subject to the provisions of Section 10(a) relating to Capitalization Adjustments the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options shall be 1,658,377 shares of Common Stock plus the amount of any increase in the number of shares that may be available for issuance pursuant to Stock Awards pursuant to Section 4(a).


A-8


Table of Contents

(c) Source of Shares.  The stock issuable under the Plan shall be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market.
 
5.   Eligibility.
 
(a) Eligibility for Specific Stock Awards.  Incentive Stock Options may be granted only to Employees. Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants.
 
(b) Ten Percent Stockholders.  A Ten Percent Stockholder shall not be granted an Incentive Stock Option unless the exercise price of such Option is at least one hundred ten percent (110%) of the Fair Market Value of the Common Stock on the date of grant and the Option is not exercisable after the expiration of five (5) years from the date of grant.
 
(c) Section 162(m) Limitation on Annual Grants.  Subject to the provisions of Section 10(a) relating to Capitalization Adjustments, at such time as the Company may be subject to the applicable provisions of Section 162(m) of the Code, no Employee shall be eligible to be granted Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least one hundred percent (100%) of the Fair Market Value of the Common Stock on the date the Stock Award is granted covering more than two hundred thousand (200,000) shares of Common Stock during any calendar year.
 
(d) Consultants.  A Consultant shall not be eligible for the grant of a Stock Award if, at the time of grant, a Form S-8 Registration Statement under the Securities Act (“Form S-8”) is not available to register either the offer or the sale of the Company’s securities to such Consultant because of the nature of the services that the Consultant is providing to the Company, because the Consultant is not a natural person, or because of any other rule governing the use of Form S-8.
 
6.   Option Provisions.
 
Each Option shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. All Options shall be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates shall be issued for shares of Common Stock purchased on exercise of each type of Option. The provisions of separate Options need not be identical; provided, however, that each Option Agreement shall include (through incorporation of provisions hereof by reference in the Option or otherwise) the substance of each of the following provisions:
 
(a) Term.  The Board shall determine the term of an Option; provided, however, that subject to the provisions of Section 5(b) regarding Ten Percent Stockholders, no Incentive Stock Option shall be exercisable after the expiration of ten (10) years from the date of grant.
 
(b) Exercise Price of an Incentive Stock Option.  Subject to the provisions of Section 5(b) regarding Ten Percent Stockholders, the exercise price of each Incentive Stock Option shall be not less than one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the Option on the date the Option is granted. Notwithstanding the foregoing, an Incentive Stock Option may be granted with an exercise price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another option in a manner consistent with the provisions of Section 424(a) of the Code.
 
(c) Exercise Price of a Nonstatutory Stock Option.  The exercise price of each Nonstatutory Stock Option shall be not less than one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the Option on the date the Option is granted. Notwithstanding the foregoing, a Nonstatutory Stock Option may be granted with an exercise price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another option in a manner consistent with the provisions of Section 424(a) of the Code.
 
(d) Consideration.  The purchase price of Common Stock acquired pursuant to the exercise of an Option shall be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below. The Board shall have the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to


A-9


Table of Contents

use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. The methods of payment permitted by this Section 6(d) are:
 
(i) by cash or check;
 
(ii) pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds; provided, however, that such program is not in violation of the prohibition on the extension of credit to the Company’s executive officers and Directors under Section 402 of the Sarbanes-Oxley Act of 2002, in the opinion of counsel acceptable to the Company;
 
(iii) by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;
 
(iv) by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; provided, however, the Company shall accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued; provided, however, shares of Common Stock will no longer be outstanding under an Option and will not be exercisable thereafter to the extent that (i) shares are used to pay the exercise price pursuant to the “net exercise,” (ii) shares are delivered to the Participant as a result of such exercise, and (iii) shares are withheld to satisfy tax withholding obligations; or
 
(v) according to a deferred payment or similar arrangement with the Optionholder; provided, however, that interest shall compound at least annually and shall be charged at the minimum rate of interest necessary to avoid (i) the imputation of interest income to the Company and compensation income to the Optionholder under any applicable provisions of the Code, and (ii) the classification of the Option as a liability for financial accounting purposes.
 
(e) Transferability of Options.  The Board may, in its sole discretion, impose such limitations on the transferability of Options as the Board shall determine. In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options shall apply:
 
(i) Restrictions on Transfer.  An Option shall not be transferable except by will or by the laws of descent and distribution and shall be exercisable during the lifetime of the Optionholder only by the Optionholder.
 
(ii) Domestic Relations Orders.  Notwithstanding the foregoing, an Option may be transferred pursuant to a domestic relations order.
 
(iii) Beneficiary Designation.  Notwithstanding the foregoing, the Optionholder may, by delivering written notice to the Company, in a form provided by or otherwise satisfactory to the Company, designate a third party who, in the event of the death of the Optionholder, shall thereafter be the beneficiary of an Option with the right to exercise the Option and receive the Common Stock or other consideration resulting from an Option exercise.
 
(f) Vesting Generally.  The total number of shares of Common Stock subject to an Option may vest and therefore become exercisable in periodic installments that may or may not be equal. The Option may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on performance or other criteria) as the Board may deem appropriate. The vesting provisions of individual Options may vary. The provisions of this Section 6(f) are subject to any Option provisions governing the minimum number of shares of Common Stock as to which an Option may be exercised.
 
(g) Termination of Continuous Service.  In the event that an Optionholder’s Continuous Service terminates (other than for Cause or upon the Optionholder’s death or Disability), the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the


A-10


Table of Contents

date of termination of Continuous Service) but only within such period of time ending on the earlier of (i) the date three (3) months following the termination of the Optionholder’s Continuous Service (or such longer or shorter period specified in the Option Agreement), or (ii) the expiration of the term of the Option as set forth in the Option Agreement. If, after termination of Continuous Service, the Optionholder does not exercise his or her Option within the time specified herein or in the Option Agreement (as applicable), the Option shall terminate.
 
(h) Extension of Termination Date.  An Optionholder’s Option Agreement may provide that if the exercise of the Option following the termination of the Optionholder’s Continuous Service (other than upon the Optionholder’s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option shall terminate on the earlier of (i) the expiration of a period of three (3) months after the termination of the Optionholder’s Continuous Service during which the exercise of the Option would not be in violation of such registration requirements, or (ii) the expiration of the term of the Option as set forth in the Option Agreement.
 
(i) Disability of Optionholder.  In the event that an Optionholder’s Continuous Service terminates as a result of the Optionholder’s Disability, the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date twelve (12) months following such termination of Continuous Service (or such longer or shorter period specified in the Option Agreement), or (ii) the expiration of the term of the Option as set forth in the Option Agreement. If, after termination of Continuous Service, the Optionholder does not exercise his or her Option within the time specified herein or in the Option Agreement (as applicable), the Option shall terminate.
 
(j) Death of Optionholder.  In the event that (i) an Optionholder’s Continuous Service terminates as a result of the Optionholder’s death, or (ii) the Optionholder dies within the period (if any) specified in the Option Agreement after the termination of the Optionholder’s Continuous Service for a reason other than death, then the Option may be exercised (to the extent the Optionholder was entitled to exercise such Option as of the date of death) by the Optionholder’s estate, by a person who acquired the right to exercise the Option by bequest or inheritance or by a person designated as the beneficiary of the Option upon the Optionholder’s death, but only within the period ending on the earlier of (i) the date eighteen (18) months following the date of death (or such longer or shorter period specified in the Option Agreement), or (ii) the expiration of the term of such Option as set forth in the Option Agreement. If, after the Optionholder’s death, the Option is not exercised within the time specified herein or in the Option Agreement (as applicable), the Option shall terminate. If the Optionholder designates a third party beneficiary of the Option in accordance with Section 6(e)(iii), then upon the death of the Optionholder such designated beneficiary shall have the sole right to exercise the Option and receive the Common Stock or other consideration resulting from the Option exercise.
 
(k) Termination for Cause.  In the event that an Optionholder’s Continuous Service is terminated for Cause, the Option shall terminate immediately and cease to remain outstanding.
 
7.   Provisions of Stock Awards other than Options.
 
(a) Stock Purchase Awards.  Each Stock Purchase Award Agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. At the Board’s election, shares of Common Stock may be (i) held in book entry form subject to the Company’s instructions until any restrictions relating to the Stock Purchase Award lapse; or (ii) evidenced by a certificate, which certificate shall be held in such form and manner as determined by the Board. The terms and conditions of Stock Purchase Award Agreements may change from time to time, and the terms and conditions of separate Stock Purchase Award Agreements need not be identical; provided, however, that each Stock Purchase Award Agreement shall include (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:
 
(i) Purchase Price.  At the time of the grant of a Stock Purchase Award, the Board will determine the price to be paid by the Participant for each share subject to the Stock Purchase Award. To the extent required by applicable law, the price to be paid by the Participant for each share of the Stock Purchase Award will not be less than the par value of a share of Common Stock.


A-11


Table of Contents

(ii) Consideration.  At the time of the grant of a Stock Purchase Award, the Board will determine the consideration permissible for the payment of the purchase price of the Stock Purchase Award. The purchase price of Common Stock acquired pursuant to the Stock Purchase Award shall be paid either: (i) in cash or by check at the time of purchase, (ii) at the discretion of the Board, according to a deferred payment or other similar arrangement with the Participant, (iii) by past or future services rendered to the Company or an Affiliate, or (iv) in any other form of legal consideration that may be acceptable to the Board in its sole discretion and permissible under applicable law.
 
(iii) Vesting.  Shares of Common Stock acquired under a Stock Purchase Award may be subject to a share repurchase right or option in favor of the Company in accordance with a vesting schedule to be determined by the Board.
 
(iv) Termination of Participant’s Continuous Service.  In the event that a Participant’s Continuous Service terminates, the Company shall have the right, but not the obligation, to repurchase or otherwise reacquire, any or all of the shares of Common Stock held by the Participant that have not vested as of the date of termination under the terms of the Stock Purchase Award Agreement. At the Board’s election, the price paid for all shares of Common Stock so repurchased or reacquired by the Company may be at the lesser of: (i) the Fair Market Value on the relevant date, or (ii) the Participant’s original cost for such shares. The Company shall not be required to exercise its repurchase or reacquisition option until at least six (6) months (or such longer or shorter period of time necessary to avoid classification of the Option as a liability for financial accounting purposes) have elapsed following the Participant’s purchase of the shares of stock acquired pursuant to the Stock Purchase Award unless otherwise determined by the Board or provided in the Stock Purchase Award Agreement.
 
(v) Transferability.  Rights to purchase or receive shares of Common Stock granted under a Stock Purchase Award shall be transferable by the Participant only upon such terms and conditions as are set forth in the Stock Purchase Award Agreement, as the Board shall determine in its sole discretion, and so long as Common Stock awarded under the Stock Purchase Award remains subject to the terms of the Stock Purchase Award Agreement.
 
(b) Stock Bonus Awards.  Each Stock Bonus Award Agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. At the Board’s election, shares of Common Stock may be (i) held in book entry form subject to the Company’s instructions until any restrictions relating to the Stock Bonus Award lapse; or (ii) evidenced by a certificate, which certificate shall be held in such form and manner as determined by the Board. The terms and conditions of Stock Bonus Award Agreements may change from time to time, and the terms and conditions of separate Stock Bonus Award Agreements need not be identical, provided, however, that each Stock Bonus Award Agreement shall include (through incorporation of provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:
 
(i) Consideration.  A Stock Bonus Award may be awarded in consideration for (i) past or future services rendered to the Company or an Affiliate, or (ii) any other form of legal consideration that may be acceptable to the Board in its sole discretion and permissible under applicable law.
 
(ii) Vesting.  Shares of Common Stock awarded under the Stock Bonus Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board.
 
(iii) Termination of Participant’s Continuous Service.  In the event a Participant’s Continuous Service terminates, the Company may receive via a forfeiture condition, any or all of the shares of Common Stock held by the Participant which have not vested as of the date of termination of Continuous Service under the terms of the Stock Bonus Award Agreement.
 
(iv) Transferability.  Rights to acquire shares of Common Stock under the Stock Bonus Award Agreement shall be transferable by the Participant only upon such terms and conditions as are set forth in the Stock Bonus Award Agreement, as the Board shall determine in its sole discretion, so long as Common Stock awarded under the Stock Bonus Award Agreement remains subject to the terms of the Stock Bonus Award Agreement.


A-12


Table of Contents

(c) Stock Unit Awards.  Each Stock Unit Award Agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. The terms and conditions of Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Stock Unit Award Agreements need not be identical, provided, however, that each Stock Unit Award Agreement shall include (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:
 
(i) Consideration.  At the time of grant of a Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board in its sole discretion and permissible under applicable law.
 
(ii) Vesting.  At the time of the grant of a Stock Unit Award, the Board may impose such restrictions or conditions to the vesting of the Stock Unit Award as it, in its sole discretion, deems appropriate.
 
(iii) Payment.  A Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Stock Unit Award Agreement.
 
(iv) Additional Restrictions.  At the time of the grant of a Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Stock Unit Award after the vesting of such Stock Unit Award.
 
(v) Dividend Equivalents.  Dividend equivalents may be credited in respect of shares of Common Stock covered by a Stock Unit Award, as determined by the Board and contained in the Stock Unit Award Agreement. At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Stock Unit Award credited by reason of such dividend equivalents will be subject to all the terms and conditions of the underlying Stock Unit Award Agreement to which they relate.
 
(vi) Termination of Participant’s Continuous Service.  Except as otherwise provided in the applicable Stock Unit Award Agreement, such portion of the Stock Unit Award that has not vested will be forfeited upon the Participant’s termination of Continuous Service.
 
(d) Stock Appreciation Rights.  Each Stock Appreciation Right Agreement shall be in such form and shall contain such terms and conditions as the Board shall deem appropriate. The terms and conditions of Stock Appreciation Right Agreements may change from time to time, and the terms and conditions of separate Stock Appreciation Right Agreements need not be identical; provided, however, that each Stock Appreciation Right Agreement shall include (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:
 
(i) Strike Price and Calculation of Appreciation.  Each Stock Appreciation Right will be denominated in shares of Common Stock equivalents. The appreciation distribution payable on the exercise of a Stock Appreciation Right will be not greater than an amount equal to the excess of (i) the aggregate Fair Market Value (on the date of the exercise of the Stock Appreciation Right) of a number of shares of Common Stock equal to the number of share of Common Stock equivalents in which the Participant is vested under such Stock Appreciation Right, and with respect to which the Participant is exercising the Stock Appreciation Right on such date, over (ii) an amount (the strike price) that will be determined by the Board at the time of grant of the Stock Appreciation Right.
 
(ii) Vesting.  At the time of the grant of a Stock Appreciation Right, the Board may impose such restrictions or conditions to the vesting of such Stock Appreciation Right as it, in its sole discretion, deems appropriate.
 
(iii) Exercise.  To exercise any outstanding Stock Appreciation Right, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such Stock Appreciation Right.


A-13


Table of Contents

(iv) Payment.  The appreciation distribution in respect to a Stock Appreciation Right may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Stock Appreciation Right Agreement evidencing such Stock Appreciation Right.
 
(v) Termination of Continuous Service.  In the event that a Participant’s Continuous Service terminates, the Participant may exercise his or her Stock Appreciation Right (to the extent that the Participant was entitled to exercise such Stock Appreciation Right as of the date of termination) but only within such period of time ending on the earlier of (i) the date three (3) months following the termination of the Participant’s Continuous Service (or such longer or shorter period specified in the Stock Appreciation Right Agreement), or (ii) the expiration of the term of the Stock Appreciation Right as set forth in the Stock Appreciation Right Agreement. If, after termination, the Participant does not exercise his or her Stock Appreciation Right within the time specified herein or in the Stock Appreciation Right Agreement (as applicable), the Stock Appreciation Right shall terminate.
 
(e) Performance Stock Awards.  A Performance Stock Award is any Stock Award that may be granted, may vest, or may be exercised based upon service conditions, upon the attainment during a Performance Period of certain Performance Goals, or both. The length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained shall be conclusively determined by the Board in its sole discretion. The maximum benefit to be received by any individual in any calendar year attributable to Performance Stock Awards shall not exceed the value of two hundred thousand (200,000) shares of Common Stock.
 
(f) Other Stock Awards.  Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock may be granted either alone or in addition to Stock Awards provided for under Section 6 and the preceding provisions of this Section 7. Subject to the provisions of the Plan, the Board shall have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.
 
8.   Covenants of the Company.
 
(a) Availability of Shares.  During the terms of the Stock Awards, the Company shall keep available at all times the number of shares of Common Stock required to satisfy such Stock Awards.
 
(b) Securities Law Compliance.  The Company shall seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; provided, however, that this undertaking shall not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company shall be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained.
 
9.   Miscellaneous.
 
(a) Use of Proceeds.  Proceeds from the sale of shares of Common Stock pursuant to Stock Awards shall constitute general funds of the Company.
 
(b) Stockholder Rights.  No Participant shall be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Stock Award unless and until such Participant has satisfied all requirements for exercise of the Stock Award pursuant to its terms.
 
(c) No Employment or Other Service Rights.  Nothing in the Plan, any Stock Award Agreement or other instrument executed thereunder or any Stock Award granted pursuant thereto shall confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or shall affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with


A-14


Table of Contents

or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.
 
(d) Incentive Stock Option $100,000 Limitation.  To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds one hundred thousand dollars ($100,000), the Options or portions thereof that exceed such limit (according to the order in which they were granted) shall be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).
 
(e) Investment Assurances.  The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Stock Award, (i) to give written assurances satisfactory to the Company as to the Participant’s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Stock Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant’s own account and not with any present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, shall be inoperative if (i) the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (ii) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.
 
(f) Withholding Obligations.  To the extent provided by the terms of a Stock Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to a Stock Award by any of the following means (in addition to the Company’s right to withhold from any compensation paid to the Participant by the Company) or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award; provided, however, that no shares of Common Stock are withheld with a value exceeding the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of the Stock Award as a liability for financial accounting purposes); or (iii) by such other method as may be set forth in the Stock Award Agreement.
 
(g) Electronic Delivery.  Any reference herein to a “written” agreement or document shall include any agreement or document delivered electronically or posted on the Company’s intranet.
 
10.   Adjustments upon Changes in Common Stock; Corporate Transactions.
 
(a) Capitalization Adjustments.  If any change is made in, or other events occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the effective date of the Plan set forth in Section 13 without the receipt of consideration by the Company (through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other transaction not involving the receipt of consideration by the Company (each a “Capitalization Adjustment”)), the Board shall appropriately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 4(a), (ii) the class(es) and number of securities subject to each outstanding stock award under the Prior Plan that are added from time to time to the share reserve under the Plan pursuant to Section 4(a), (iii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 4(b), (iv) the class(es) and maximum number of securities that may be awarded to any person pursuant to Sections 5(c) and 7(e), and (v) the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards. The


A-15


Table of Contents

Board shall make such adjustments, and its determination shall be final, binding and conclusive. (Notwithstanding the foregoing, the conversion of any convertible securities of the Company shall not be treated as a transaction “without receipt of consideration” by the Company.)
 
(b) Dissolution or Liquidation.  In the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to the Company’s right of repurchase) shall terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company’s repurchase option may be repurchased by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, provided, however, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.
 
(c) Corporate Transaction.  The following provisions shall apply to Stock Awards in the event of a Corporate Transaction unless otherwise provided in a written agreement between the Company or any Affiliate and the holder of the Stock Award:
 
(i) Stock Awards May Be Assumed.  In the event of a Corporate Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company) may assume or continue any or all Stock Awards outstanding under the Plan or may substitute similar stock awards for Stock Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Stock Awards may be assigned by the Company to the successor of the Company (or the successor’s parent company, if any), in connection with such Corporate Transaction. A surviving corporation or acquiring corporation may choose to assume or continue only a portion of a Stock Award or substitute a similar stock award for only a portion of a Stock Award. The terms of any assumption, continuation or substitution shall be set by the Board in accordance with the provisions of Section 3(b).
 
(ii) Stock Awards Held by Current Participants.  In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the “Current Participants”), the vesting of such Stock Awards (and, if applicable, the time at which such Stock Awards may be exercised) shall (contingent upon the effectiveness of the Corporate Transaction) be accelerated in full to a date prior to the effective time of such Corporate Transaction as the Board shall determine (or, if the Board shall not determine such a date, to the date that is five (5) days prior to the effective time of the Corporate Transaction), and such Stock Awards shall terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Stock Awards shall lapse (contingent upon the effectiveness of the Corporate Transaction). No vested Stock Unit Award shall terminate pursuant to this Section 10(c)(ii) without being settled by delivery of shares of Common Stock, their cash equivalent, any combination thereof, or in any other form of consideration, as determined by the Board, prior to the effective time of the Corporate Transaction.
 
(iii) Stock Awards Held by Former Participants.  In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, the vesting of such Stock Awards (and, if applicable, the time at which such Stock Award may be exercised) shall not be accelerated and such Stock Awards (other than a Stock Award consisting of vested and outstanding shares of Common Stock not subject to the Company’s right of repurchase) shall terminate if not exercised (if applicable) prior to the effective time of the Corporate Transaction; provided, however, that any reacquisition or repurchase rights held by the Company with respect to such Stock Awards shall not terminate and may continue to be exercised notwithstanding the Corporate Transaction. No vested


A-16


Table of Contents

Stock Unit Award shall terminate pursuant to this Section 10(c)(iii) without being settled by delivery of shares of Common Stock, their cash equivalent, any combination thereof, or in any other form of consideration, as determined by the Board, prior to the effective time of the Corporate Transaction.
 
(iv) Payment for Stock Awards in Lieu of Exercise.  Notwithstanding the foregoing, in the event a Stock Award will terminate if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Stock Award may not exercise such Stock Award but will receive a payment, in such form as may be determined by the Board, equal in value to the excess, if any, of (i) the value of the property the holder of the Stock Award would have received upon the exercise of the Stock Award, over (ii) any exercise price payable by such holder in connection with such exercise.
 
(d) Change in Control.  A Stock Award may be subject to additional acceleration of vesting and exercisability upon or after a Change in Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and the Participant. A Stock Award may vest as to all or any portion of the shares subject to the Stock Award (i) immediately upon the occurrence of a Change in Control, whether or not such Stock Award is assumed, continued, or substituted by a surviving or acquiring entity in the Change in Control, or (ii) in the event a Participant’s Continuous Service is terminated, actually or constructively, within a designated period following the occurrence of a Change in Control. In the absence of such provisions, no such acceleration shall occur.
 
11.   Amendment of the Plan and Stock Awards.
 
(a) Amendment of Plan.  Subject to the limitations, if any, of applicable law, the Board at any time, and from time to time, may amend the Plan. However, except as provided in Section 10(a) relating to Capitalization Adjustments, no amendment shall be effective unless approved by the stockholders of the Company to the extent stockholder approval is necessary to satisfy applicable law.
 
(b) Stockholder Approval.  The Board, in its sole discretion, may submit any other amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of Section 162(m) of the Code and the regulations thereunder regarding the exclusion of performance-based compensation from the limit on corporate deductibility of compensation paid to Covered Employees.
 
(c) Contemplated Amendments.  It is expressly contemplated that the Board may amend the Plan in any respect the Board deems necessary or advisable to provide eligible Employees with the maximum benefits provided or to be provided under the provisions of the Code and the regulations promulgated thereunder relating to Incentive Stock Options and/or to bring the Plan and/or Incentive Stock Options granted under it into compliance therewith.
 
(d) No Impairment of Rights.  Rights under any Stock Award granted before amendment of the Plan shall not be impaired by any amendment of the Plan unless (i) the Company requests the consent of the affected Participant, and (ii) such Participant consents in writing.
 
(e) Amendment of Stock Awards.  The Board, at any time and from time to time, may amend the terms of any one or more Stock Awards, including, but not limited to, amendments to provide terms more favorable than previously provided in the Stock Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; provided, however, that the rights under any Stock Award shall not be impaired by any such amendment unless (i) the Company requests the consent of the affected Participant, and (ii) such Participant consents in writing.
 
12.   Termination or Suspension of the Plan.
 
(a) Plan Term.  The Board may suspend or terminate the Plan at any time. Unless sooner terminated, the Plan shall terminate on the day before the tenth (10th) anniversary of the earlier of (i) the date the Plan is adopted by the Board, or (ii) the date the Plan is approved by the stockholders of the Company. No Stock Awards may be granted under the Plan while the Plan is suspended or after it is terminated.


A-17


Table of Contents

(b) No Impairment of Rights.  Suspension or termination of the Plan shall not impair rights and obligations under any Stock Award granted while the Plan is in effect except with the written consent of the affected Participant.
 
13.   Effective Date of Plan.
 
The Plan shall become effective on the IPO Date, but no Stock Award shall be exercised (or, in the case of a Stock Purchase Award, Stock Bonus Award, Stock Unit Award, or Other Stock Award shall be granted) unless and until the Plan has been approved by the stockholders of the Company, which approval shall be within twelve (12) months before or after the date the Plan is adopted by the Board.
 
14.   Choice of Law.
 
The law of the State of Delaware shall govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state’s conflict of laws rules.


A-18


Table of Contents

PLEASE REFER TO THE REVERSE SIDE FOR TELEPHONE AND INTERNET VOTING INSTRUCTIONS
A Election of Directors
1. The Board of Directors recommends a vote FOR the listed nominees.
         
01 – Bernard A. Hausen, M.D., Ph.D.
  Withhold   For
 
  o   o
 
       
02 – J. Michael Egan
  Withhold   For
 
  o   o
 
       
03 – Kevin T. Larkin
  Withhold   For
 
  o   o
 
       
04 – Richard P. Powers
  Withhold   For
 
  o   o
 
       
05 – Jeffrey L. Purvin
  Withhold   For
 
  o   o
 
       
06 – Robert C. Robbins, M.D.
  Withhold   For
 
  o   o
 
       
07 – John Simon, Ph.D.
  Withhold   For
 
  o   o
 
       
08 – Stephen A. Yencho
  Withhold   For
 
  o   o
 
       
09 – William H. Younger, Jr.
  Withhold   For
 
  o   o


Table of Contents

B Other Proposals
The Board of Directors recommends a vote FOR the following proposals:
2. To approve an amendment to the Company’s 2005 Equity Incentive Plan (the “2005 Plan”) to increase the aggregate number of shares of common stock authorized for issuance under the 2005 Plan by 500,000 shares.
                 
    Withhold   For   Abstain    
    o   o   o    
3. To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as independent registered public accounting firm of the Company for its fiscal year ending June 30, 2009.
                 
    Withhold   For   Abstain    
    o   o   o    
C Authorized Signatures — Sign Here — This section must be completed for your instructions to be executed.
Please sign exactly as your name(s) appear on Proxy. If held in joint tenancy, all persons must sign. Trustees, administrators, etc., should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing the proxy.
         
Signature 1 — Please keep signature within the box
  Signature 2 — Please keep signature within the box   Date (mm/dd/yyyy)
 
       
ANNUAL MEETING OF STOCKHOLDERS
Wednesday, November 19, 2008
11:30 a.m.
Cardica, Inc.
900 Saginaw Drive
Redwood City, CA 94063

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki